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ABSTRACT
Background: Allergic disorders, including eczema, asthma, and rhinitis, have emerged
as a global public health concern due to their elevated prevalence and the associated
clinical morbidity. Environmental, immunologic, and genetic factors have been
implicated in the pathogenesis of allergic disorders. Allergic sensitization (representing
deviated immune responses) and filaggrin gene (FLG) variants (leading to dysfunctional
epidermal barrier) have shown to be common predisposing factors in the development of
allergic disorders. However, there is a lack of knowledge on their joint effects on the
development of single and multiple (coexistence) allergic disorders. More recently,
epigenetic mechanisms, such as DNA methylation, have emerged as potentially important
factors in the development of such complex diseases; however, the extent to which DNA
methylation associates with allergic disorders is unclear.
Objectives: This dissertation sought to (i) determine whether eczema and/or allergic
sensitization is an effect modifier of the association between ‘FLG variants and asthma’
and ‘FLG variants and rhinitis’, (ii) test whether FLG variants and allergic sensitization
jointly predispose to the comorbidity of eczema, asthma and rhinitis, and (iii) examine
associations between DNA methylation across the epidermal differentiation complex
(EDC) genomic region with eczema status.
Methods: The Isle of Wight (IOW) birth cohort, a population-based sample of 1,456
infants born between January 1989 and February 1990, was prospectively assessed at
ages 1, 2, 4, 10, and 18 years. Repeated measurements of eczema, asthma, rhinitis, and
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allergic sensitization (documented by skin prick tests) were available for all follow-ups.
FLG variants R501X, 2282del4, and S3247X were genotyped in 1,150 participants. Logbinomial regression models were applied to test for associations and statistical
interactions on multiplicative scale. On the other hand, DNA methylation was measured
in a subsample (n = 367) of the IOW participants at age 18 years (discovery cohort) and
in two semi-independent samples (replication cohorts I and II). Associations between
eczema status and DNA methylation were assessed using linear regression.
Results: FLG variants were associated with increased risk of asthma and rhinitis. Both
eczema status (RRinteraction = 1.96, Pinteraction = 0.006) and allergic sensitization (RRinteraction
= 1.58, Pinteraction = 0.013) modified the association between FLG variants and asthma, but
not the association with rhinitis. The combined effect of both risk factors increased the
risk of coexisting “eczema and asthma” (RR = 13.67, 95% CI: 7.35 – 25.42), “asthma and
rhinitis” (RR = 7.46, 95% CI: 5.07 – 10.98), and “eczema, asthma, and rhinitis” (RR =
23.44, 95% CI: 12.27 – 44.78). On the other hand, Differential DNA methylation of CpG
site cg12048339 (located within promoter of S100A6 gene) was associated with eczema
specifically among female participants of all study cohorts; whereas, aberrant DNA
methylation of cg10959711 (located within promoter of S100A11 gene) associated with
eczema among male participants in all study samples.
Conclusions: Allergic sensitization and eczema modulated the association between FLG
variants and asthma, but not rhinitis; implying that the mechanisms and pathways through
which FLG variants predispose to increased risk of asthma and rhinitis may be different.
Moreover, the coexistence of allergic disorders is frequent and allergic sensitization and
FLG variants jointly increased risk of allergic comorbidities, which may represent more
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severe and complex clinical phenotypes. Results of an exploratory investigation
demonstrated that DNA methylation of the EDC locus could be an important factor in the
development of eczema in a sex-specific manner. Future studies corroborating our
findings are needed.
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CHAPTER 1
INTRODUCTION
1.1 BACKGROUND
Allergic disorders, including eczema, asthma, and rhinitis, have emerged as a
global public health concern [1]. The clinical morbidity associated with allergic disorders
that leads to social and economic burden on families and societies further classify these
disorders as major global public-health challenges [1, 2]. The direct annual cost
associated with clinical management of eczema alone was estimated to be £47 ($76)
million in the United Kingdom, with families bearing £17 ($27) million of disease costs
[3]. Furthermore, Asthma has even greater economic burden, costing £843 million
($1.368 billion) annually [3]. The elevated economic burden and clinical morbidity
associated with such chronic diseases, clearly demonstrates the need for developing costeffective intervention and prevention strategies that aim at reducing the burden associated
with allergic disorders. However, to reach the aforementioned goal, there is a need to
better understand the natural history and the biological mechanisms that underlie the
clinical manifestation of these complex disorders at different developmental stages.
The International Study of Asthma and Allergies in Childhood (ISAAC) provides
unmatched opportunity to explore the trends in prevalence of allergic disorders over time
[4]. Reports based on the ISAAC study revealed the existence of global variations in the
prevalence of allergic disorders [5-8]. During the last 3 decades, industrialized nations
witnessed disproportionally increased trends in the prevalence of eczema, asthma, and
1

rhinitis [5, 9]. However, recent reports are indicating that a plateau in the prevalence has
been reached in most of the countries that experienced increasing trends [10-12]. In
contrast, countries with formerly low-prevalence are reporting increasing patterns in the
prevalence and incidence of allergic disorders [10-13]. The disparity in the prevalence
across nations and the changing trends over time within populations are indicators of the
importance of environmental factors, in addition to the genetic elements, in disease
pathogenesis. Deeper understanding of the natural history and risk factors of these
chronic conditions will help us elucidate their plausible underlying etiological
mechanisms.

1.2 OVERALL STRUCTURE OF THE DISSERTATION
This document is divided into six chapters, as the following:
i.

The first chapter provides background information on the dissertation topic,
literature review relevant to the study questions, current gap in knowledge, and
the specific aims and hypotheses of this study.

ii.

The second chapter explains in details the methodological parts of the study and
the statistical analyses that were applied to achieve the goals of this dissertation.

iii.

Each of chapter three, four, and five is organized and formatted as a journal
research report that have been or will be submitted for publication. Each of these
three research-related chapters, also referred to as results chapters, represent one
of the three specific aims of this dissertation.
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iv.

The sixth, last, chapter provides an overall synopsis and discussion of the results
of the three research-related chapters and how results of these chapters are
synthesized.

1.3 LITERATURE REVIEW
1.3.1 GLOBAL VARIATIONS IN THE PREVALENCE OF ALLERGIC DISORDERS
Reports based on the ISAAC study revealed the existence of global variations and
both between and within countries variations in the prevalence of allergic disorders [5,
10, 11, 14, 15]. For instance, for the age group 6 to 7 years, data based on the ISAAC
study showed that the 12-month prevalence of eczema ranged from 0.9% in India to
22.5% in Ecuador [14]. For the age group 13 to 14 years, the prevalence of eczema
between countries ranged from 0.2% in China to 24.6% in Columbia [14]. Similarly, the
prevalence of asthma symptoms among 13 to 14 years old children ranged from 0.1% in
Pune (India) to 16% in Costa Rica [16]. Prevalence of rhinitis showed even wider global
variation, which ranged from 1% in India to 45.1% in Paraguay [17]. In addition to
estimating the prevalence and time trends of allergic disorders, the ISAAC study allowed
researcher to discover wide-range of geographical differences in the prevalence of
eczema within countries. For example, the ISAAC phase 3 study was conducted in 10
different locations across Spain, with the lifetime prevalence among 6 to 7 years olds
being 35.6% in ‘A Coruna’ and 25.0% in ‘Barcelona’ [14]. Although the role of
environmental factors in explaining the between and within countries variations in
allergic disorders prevalence is essential, there is some strong evidence suggesting that
genetic predisposition can potentiate the effects of environmental factors [18]. In
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summary, both the between and within countries differences in the prevalence of allergic
disorders are worth remarking as they can contribute to the advancement of etiologic
research.

1.3.2 NATURAL HISTORY OF ALLERGIC DISORDERS
Eczema is an inflammatory skin disorder that is characterized by disrupted
epidermal barrier function, immunoglobulin E (IgE)-mediated sensitization to food and
environmental allergens (i.e., allergic sensitization), and a remitting–relapsing
combination of skin dryness and itching [19-21]. Globally, the prevalence of eczema
among children and adults has been estimated to be between 15% to 30% and 2% to
10%, respectively, demonstrating wide variation across nations [20, 22]. The three major
developmental periods of eczema are: infancy, childhood, and adolescence/adulthood;
with 45% of all eczema cases occurring in the first 6 months of life [20, 23]. However,
the long-term prognosis (natural history) of eczema is complex due to the relapsing and
remitting nature of the disease. Emerging evidence is suggesting that eczema affects
more boys during early life stages and becomes more predominant among adolescent
girls and thereafter [20, 24]. Recently, we demonstrated that girls develop more eczema
during puberty period while more boys outgrow their eczema [25]. Yet, more insights on
the etiology of eczema are needed in order for preventable public-health efforts to
succeed.
Likewise, population-based studies have shown that the prevalence of both
asthma and rhinitis is increasing and disproportionally affecting developed and
developing countries [10]. Asthma, accounting for a substantial proportion of
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burden/morbidity associated with allergic disorders, is a common chronic disorder
affecting up to 25% of children and adults around the world [16, 26-29]. The major
pathophysiological hallmarks that contribute to the complex heterogeneity of the clinical
manifestations of asthma are recurrent airway inflammation, variable airway obstruction,
and bronchial hyper-responsiveness [30, 31]. Similarly, an increase in the prevalence of
rhinitis (10% to 30%), which is an inflammatory disease affecting the nasal tissue, has
been documented during the last 30 years [32]. Common symptoms of rhinitis are nasal
congestion and itching, sneezing, and rhinorrhoea, which negatively impact the quality of
life [32, 33]. The natural history of both asthma and rhinitis is influenced by gender [34,
35]. For asthma, a gender reversal occurs around the puberty period; the disorder
predominantly affects boys before puberty, whereas, more girls are affected during
adolescence and in early adulthood [26, 35-37]. However, the effect of gender on the
long-term prognosis of rhinitis is further complicated by allergic sensitization (defined
later) [33, 34].
Although it is acceptable to investigate the etiological mechanisms underlying
allergic diseases separately; evidence supporting their comorbidity is increasing [38, 39].
Allergic comorbidity (coexistence) is defined as the concurrent presence of more than
one allergic disorder (i.e. eczema, asthma, and rhinitis) in the same individual. The
elevated comorbidity of asthma (lower-airway disorder) and rhinitis (upper-airways
disorder) and their shared pathophysiology further support the concept of “one airway
one disease” [12, 40]. In addition to the comorbidity of the allergic respiratory diseases,
the concept of “allergic march” suggests that allergic diseases develop in a sequential
pattern. Eczema is considered as the first step in the allergic march, usually developing
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early in infancy/childhood followed by manifestations of allergic disorders of the airway
later in childhood or early adolescence period [41]. The continuum developmental
mechanism of allergic diseases is widely discussed in the scientific literature; however,
supporting replicable evidence and high consensus is far from complete [41, 42]. Another
revealing concept is the “coexistence” of allergic morbidities, which opposes the linear
developmental pathway [42-44]. A report based on the German Multicenter Atopy Study
(MAS), showed that eczema alone early in life does not support the allergic march, rather
the coexistence of eczema and wheezing predicted asthma [45]. Such observation speaks
in favor of the coexistence of allergic morbidities instead of a progressive development.
The interrelationship between these conditions and the risk factors that either predispose
individuals to follow the “allergic march” or “coexistence” remain an open field for
research.

1.3.3 ALLERGIC SENSITIZATION AND FILAGGRIN VARIANTS: AS COMMON RISK FACTORS
A complex interplay between genetic, environmental, and immunological factors
is considered to contribute to the pathogenesis of allergic disorders [43, 46]. Allergic
sensitization, defined as the genetic susceptibility to produce Immunoglobulin E (IgE)
antibodies in response to exposure to environmental or food antigens, is the most
common thread linking the manifestations of allergic disorders [46-48]. Arshad et al
suggested that 30% to 40% of cases of eczema, asthma, and rhinitis in early childhood
can be attributed to allergic sensitization [49]. Yet, others suggested that up to 80% of
asthmatic patients have concomitants allergic sensitization [50]. Similarly, it is well
established that manifestations of eczema and rhinitis are closely associated with allergic
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sensitization [23, 32, 46, 48]. Candidate-gene and genome-wide association studies have
identified several genetic variants that are associated with the observed variability in IgE
levels between allergic and non-allergic individuals [51, 52]. As a result, genetic factors
that regulate the immune response dominated the research of allergic diseases for the last
30 to 40 years.
The recent discovery of loss-of-function variants in the filaggrin gene (FLG)
caused a shift in the research paradigm from mainly focusing on immune related genes to
incorporating genetic factors that regulate the formation of the epidermal barrier [53-55].
Filaggrin (filament-aggregating protein) is a key protein for the formation of functional
skin barrier that inhibits the penetration of allergens, microbes, and irritants and limits
transepidermal water loss [55-57]. Loss-of-function variants within the FLG are the
strongest and most replicated risk factors for eczema development, yet [58, 59]. Filaggrin
haploinsufficiency, i.e. reduction in filaggrin protein expression in heterozygous
individuals, is associated with approximately 3-fold increased risk for eczema [60, 61]. It
has been estimated that around 25% to 50% of eczema patients are carriers of at least one
FLG variant, which is associated with an estimated population-attributable risk ranging
from 4.2% to 15.2% [58, 61-63]. In addition to its association with eczema, multiple
studies showed that FLG variants are associated with asthma and rhinitis [56, 60]. One
school of thought considers that the association between FLG variants and asthma
depends on the presence of eczema [59, 64, 65]. However, there is conflicting evidence
as to whether the association between FLG variants and rhinitis is modified by eczema
status [63, 64, 66]. To this end, it is clear that FLG variants are significant common
thread for the development of the different allergic disorders.
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1.3.4 DNA METHYLATION AND THE RISK OF ECZEMA
The high heritability of eczema (71% to 84%), asthma (35% to 95%), and rhinitis
(33% to 91%) and clustering within families demonstrate the importance of genetic
predisposition in their pathogenesis [43, 67, 68]. However, thus far candidate-gene and
genome-wide association studies have failed to explain the observed high heritability of
allergic diseases. Hence, suggesting that genetic regulatory factors, other than DNA
sequence variants, such as epigenetic variants may account for the unexplained genetic
effect [69]. Epigenetic regulatory mechanisms are mitotically heritable and can alter gene
activity without changing the DNA sequence [70]. DNA methylation, widely studied in
epidemiological investigations due to practical and biological reasons [71, 72], along
with histone modifications are important epigenetic marks that work hand-in-hand on
influencing disease expression [73]. Since eczema is considered as the first manifestation
of allergic disorders that can predispose to subsequent allergic morbidities, it is thus
important to understand the epigenetic etiologic mechanisms that underlie eczema
development. Up to our knowledge, the impact of DNA methylation on the risk of
eczema has not been investigated previously. The epidermal differentiation complex
(EDC), located on human chromosome 1q21, harbors a dense cluster of genes (including
FLG) that are involved in the terminal differentiation of keratinocytes that are responsible
for the integrity and functionality of the epidermal barrier [74-76]. Previous reports
showed that a compromised epidermal barrier predispose to the development of eczema
[77, 78]. Therefore, a comprehensive DNA methylation profiling of the EDC genomic
region should provide novel insights into the epigenetic contribution in the development
of eczema.
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1.4 GAPS IN CURRENT STATE OF KNOWLEDGE
Both, allergic sensitization (deviated immune response) and FLG variants
(defective epidermal barrier) are important risk factors that link and predispose to the
development of allergic disorders[46]. However, the current state of knowledge lacks
clear understanding on the joint contribution of these two risk factors. Prior studies
focused on eczema as the effect modifier for the association between FLG variants and
asthma, while ignoring the role of allergic sensitization. Similarly, eczema was
investigated as an effect modifier for the association between FLG variants and rhinitis,
but not allergic sensitization. Furthermore, the single and joint role of FLG variants and
allergic sensitization on the coexistence of allergic diseases (i.e., eczema, asthma, and
rhinitis) has not been previously investigated. On the other hand, no existing knowledge
on the role of epigenetic regulatory mechanisms (e.g., DNA methylation) of the EDC
genomic loci that controls the epidermal barrier formation and functionality in relation to
eczema risk is available.

1.5 STUDY PROPOSAL, HYPOTHESES, AND AIMS
Population-based longitudinal studies provide an unmatched opportunity to
investigate the natural history of allergic disorders. Cross-sectional and case-control
studies lack the ability of determining the longitudinal effect of risk factors on outcomes.
However, follow-up studies with repeated measurements of the outcomes of interest (e.g.,
eczema, asthma, and rhinitis) and risk factors (e.g., allergic sensitization) facilitate the
determination of whether the effects are established early or later in the development of
diseases. Furthermore, we can determine whether the effect of time-independent risk
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factor (e.g. FLG variants) changes over-time. In contrast, for dynamic (time-varying) risk
factors (e.g., allergic sensitization) determining their concurrent effects allow the risk to
change over-time. This dissertation aims at enhancing our understanding of the role of
FLG variants, allergic sensitization, and epigenetic modifications on the development of
allergic diseases, by examining the following specific hypotheses (H):
H1: Allergic sensitization, not eczema, is the main effect modifier of the association
between FLG variants and asthma.
H2: The association between FLG variants and rhinitis is modified by allergic
sensitization status, not eczema status.
H3: FLG variants and allergic sensitization jointly increase the risk of having single and
multiple (coexisting) allergic disorders.
H4: Eczema-affected and eczema-free individuals have different DNA methylation
profiles for the EDC genomic region.
Hypothesis 1, 2, and 3 will be tested using data from the Isle of Wight 1989 birth
cohort study (n = 1,456). Participants were prospectively followed-up at the ages of 1, 2,
4, 10, and 18 years. Hypothesis 4 will be tested in a subset (n = 367) of Isle of Wight
birth cohort participants that had DNA methylation measurements. For the purpose of
validation, hypothesis 4 will be further tested in two semi-independent samples (pregnant
cohort participant, their partners, and their offspring, the F2 generation). The specific
aims (SA) of this dissertation are:
SA1: To determine the magnitude of modification imposed by eczema and allergic
sensitization on the association between “FLG variants and asthma” (H1).
Similarly, I will determine whether eczema and/or allergic sensitization act as an

10

effect modifier for the association between “FLG variants and rhinitis” (H2).
Overall, I will test whether the combined (joint) effect of two risk factors (i.e.,
“FLG variants and eczema” or “FLG variants and allergic sensitization”) yields
higher risk of asthma (or rhinitis).
SA2: To test whether FLG variants and allergic sensitization jointly predispose to the
comorbidity of eczema, asthma and rhinitis (H3).
SA3: To associate DNA methylation across the EDC genomic region with eczema status
(H4).

1.6 HOW WOULD RESULTS OF THIS DISSERTATION ENHANCE OUR KNOWLEDGE?
Better understanding of the genetic and epigenetic contribution to the
development of allergic diseases will be gained by successfully accomplishing the
specific aims of this dissertation. We have previously shown that the combined effect of
allergic sensitization and FLG variants predisposed individuals at higher risk of having
concurrent and subsequent eczema [79]. In this dissertation, I will investigate whether
allergic sensitization (or eczema) in combination with FLG variants increase the risk of
having concurrent and subsequent asthma and rhinitis. The current knowledge indicates
that FLG variants increase the risk of asthma only in the presence of eczema [59, 66];
however, I propose to test whether allergic sensitization is the effect modifier rather than
eczema. Furthermore, the current inconsistencies in the associations between FLG
variants and rhinitis can be attributed to the failure of previous studies in accounting for
the possible interaction between FLG variants and allergic sensitization on the risk of
rhinitis. Therefore, SA1 of this dissertation will enhance our knowledge by showing that
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allergic sensitization is the main effect modifier of the association between FLG variants
and asthma and FLG variants and rhinitis.
Results of SA1 of this dissertation will show the importance of FLG variants and
allergic sensitization on the development of single allergic disorders (i.e., asthma and
rhinitis). In contrast, SA2 sought to determine whether FLG variants and allergic
sensitization are associated with the coexistence of multiple allergic diseases rather than a
single morbidity. Previous etiologic research in the field of allergic comorbidities is
highly limited and assessments of the joint role of allergic sensitization and FLG variants
on the development of allergic comorbidities is lacking. Therefore, results of SA2 will
enhance our understanding of the underlying risk factors that predispose individuals at
higher risk of having multiple allergic disorders.
In addition to the role of genetic variants in the pathogenesis of allergic diseases,
the etiologic role of epigenetic modifications (e.g., DNA methylation) is rapidly
emerging and scientifically sound. Recently we showed a significant interaction between
FLG variants and adjacent differential DNA methylation on the risk of eczema [80].
Results of this report suggested that the association between FLG variants and eczema is
modulated by DNA methylation. Recent evidence is suggesting that epigenetic
mechanisms, such as DNA methylation, that alter gene activity without changing the
underlying DNA sequence account for a considerable amount of the unexplained genetic
effect found in complex diseases, such as eczema [69, 72]. In this dissertation I propose
going beyond the single-gene approach (i.e., FLG gene) into incorporating the DNA
methylation of the EDC locus at chromosome 1q21 (SA3). The EDC includes a dense
cluster of approximately 60 genes (including FLG) encoding structural and regulatory
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proteins that are essential for keratinocyte differentiation [76, 81, 82]. Comprehensively
analyzing DNA methylation status of the EDC genomic region will provide novel
insights, beyond genetic variants, on the contribution of epigenetic modifications.
Therefore, I anticipate that DNA methylation of the EDC will further show the
importance of this genomic region for the development of eczema. SA3 will focus on
eczema since it is considered the first manifestation of allergic diseases. The ultimate
goal of this dissertation is to improve our ability of characterizing and classifying
susceptible individuals, which will lead to an improved clinical management and the
development of efficient intervention and prevention strategies.
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CHAPTER 2
METHODS
2.1 STUDY DESIGN AND PARTICIPANTS
This dissertation is mainly based on information collected from the Isle of Wight
(IOW) birth cohort. An unselected population-based study (n = 1,536) was recruited
between January 1989 and February 1990 in the Isle of Wight, United Kingdom, to
prospectively study the natural history and etiology of asthma and allergic diseases. The
island is close to the British mainland, semi-rural, without heavy industry. Both the Isle
of Wight and the study populations are 99% Caucasian. After excluding adoptions,
perinatal deaths, and refusals for follow-up, written informed consent was obtained from
parents to enrol 1,456 children (95%), with follow-up assessments conducted at ages 1 (n
= 1,167), 2 (n = 1,174), 4 (n = 1,218), 10 (n = 1,373), and 18 (n = 1,313) years. Ethics
approvals were obtained from the Isle of Wight Local Research Ethics Committee (now
named the National Research Ethics Service, NRES Committee South Central –
Southampton B) at recruitment and for the 1, 2, 4, 10 and 18 years follow-ups
(06/Q1701/34). Detailed questionnaires were completed for each child at each follow-up.
When a visit was not possible, a telephone questionnaire was completed or a postal
questionnaire sent for completion and return.
For the purpose of testing H4, a subsample (discovery cohort: n = 367, aged 18
years) of the IOW birth cohort participants were randomly selected for epigenetic study.
We also considered two cohorts to test the reproducibility of results obtained from the
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discovery cohort. Replication cohort I (n = 146; parents of the F2 generation) includes
participants of the IOW cohort (28.8% were part of the discovery cohort) plus new
participants. Expecting mothers and their partners were assessed before delivery.
Replication cohort II (n = 94; F2 generation) includes the F2 newborns of the IOW cohort
participants plus new parents. Infants were followed-up at ages 3-, 6-, and 12-months.

2.2 PHENOTYPES
In all assessments of the Isle of Wight birth cohort, eczema was defined as
chronic or chronically relapsing, itchy dermatitis lasting more than 6 weeks with
characteristic morphology and distribution [83], following Hanifin and Rajka criteria
[84]. For asthma, at the 1, 2, and 4-year follow-ups, the medical investigator determined
the presence of asthma based on wheeze frequency over the last 12 months and treatment
given for asthma or asthma related symptoms. At the 10 and 18 year follow-ups, asthma
was defined as having “ever had asthma” and either “wheezing or whistling in the chest
in the last 12 months” or “current treatment for asthma”, using ISAAC questionnaire [4].
Rhinitis was defined by a positive response to: ‘In the past 12 months have you had a
problem with sneezing, or a runny or a blocked nose when you did not have a cold or the
flu?’ [33]. Since the 1-year and 2-year follow-up data on eczema, asthma, and rhinitis
were collected in a relatively small time window, we combined them for analytic
purposes (reported as 1-or-2 years).
To determine allergic sensitization status, skin prick testing (SPT) at ages 1 and 2
years was performed on children with any symptoms of eczema, asthma, or rhinitis. We
combined SPT results for ages 1 and 2 years, since they occurred within a short time
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period and will henceforth refer to this as SPT at 1-or-2 years. At 4, 10 and 18 years,
regardless of symptoms, SPT was performed on most children attending the research
center to a standard battery of common allergens (ALK-Albello, Horsholm, Denmark).
Inhalant allergens tested were house dust mite, cat, dog, Alternaria alternata,
Cladosporium herbarium, grass pollen mix, and tree pollen mix. Food allergens tested
were cows’ milk, soya, hens’ egg, peanut and cod. Positive and negative controls were
included. Allergic sensitization was defined by having a SPT to at least one allergen test
with mean wheal diameter of 3 mm greater than the negative control. Since allergic
sensitization is a dynamic rather than a completely stable phenotype, we used the
concurrent status and thus allowed the risk to change over time.

2.3 FLG GENOTYPING
DNA was extracted from blood or saliva samples from cohort subjects (n =
1,211). Five variants in the FLG gene that result in loss of function and are reported to be
common in populations of European ancestry were selected for genotyping [79]. DNA
samples were interrogated using GoldenGate Genotyping Assays (Illumina, Inc,
SanDiego, CA) on the BeadXpressVeracode platform (Illumina, Inc, SanDiego, CA) per
Illumina’s protocol. In brief, samples were fragmented and hybridized to the pool of
allele-specific primer sets. Following an extension/ligation reaction the samples were
then hybridized to the Veracode bead pool and processed on the BeadXpress reader. Data
were analyzed using the genotyping module of the GenomeStudio Software package
(Illumina, Inc, SanDiego, CA). DNA from each subject plus 37 replicate samples were
analyzed for a total of 1,248 samples. The quality threshold for allele determination was
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set at a GenCall score > 0.25 (scores ≤ 0.25 were “no calls”) with n = 1,227 samples
(98.3%) retained for further analysis. Analysis of each locus included reclustering of
genotyping data using our project data to define genotype cluster positions with
additional manual reclustering to maximize both cluster separation and the 50th
percentile of the distribution of the GenCall scores across all genotypes (50% GC score).
Children were classified as having FLG loss-of-function defect if they carry the minor
allele for at least one of the following FLG null variants: R501X, 2282del, or S3247X.
Variants 3702delG and R2447X were not informative in our population due to minor
allele frequencies being < 0.1% [79], and thus were not used in defining filaggrin
haploinsufficiency.

2.4 DNA METHYLATION PROFILING
DNA was extracted from whole blood collected at age 18 years (discovery cohort), whole
blood of replication cohort I participants’, and cord blood of replication cohort II
participants’ [85], and bisulfite-treated for cytosine to thymine conversion using the EZ
96-DNA methylation kit (Zymo Research, CA, USA). Genome-wide DNA methylation
was assessed using the Illumina Infinium HumanMethylation450 BeadChip (Illumina,
Inc., CA, USA), which interrogates > 484,000 CpG sites associated with approximately
24,000 genes. Arrays were processed using a standard protocol [86]. The BeadChips
were scanned using a BeadStation, and the methylation level (beta value) calculated for
each queried CpG locus using the Methylation Module of BeadStudio software. After
cleaning of the DNA methylation data, beta (β) values presented as the proportion of
methylated (M) over methylated (M) and unmethylated (U) sites (β=M/[c+M+U], with c
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being constant to prevent dividing by zero) were used to estimate the effect of DNA
methylation [87].

2.5 STATISTICAL ANALYSIS
Statistical analyses and approach for each of the three specific aims will be presented
separately.

2.5.1 SPECIFIC AIM 1: STATISTICAL ANALYSIS
SA1: To determine the magnitude of modification imposed by eczema and allergic
sensitization on the association between “FLG variants and asthma” (H1).
Similarly, I will determine whether eczema and/or allergic sensitization act as an
effect modifier for the association between “FLG variants and rhinitis” (H2).
Overall, I will test whether the combined (joint) effect of two risk factors (i.e.,
“FLG variants and eczema” or “FLG variants and allergic sensitization”) yields
higher risk of asthma (or rhinitis).
For all of the association analyses that will be performed to approach SA1, logbinomial (log linear) regression models will be applied to estimate risk ratios (RRs) and
their 95% confidence intervals (95% CIs) using the GENMOD procedure in SAS 9.3
(SAS, Gary, NC, USA). Since the proposed effect modifiers (i.e., allergic sensitization
and eczema) and the two outcomes (i.e., asthma and rhinitis) were measured repeatedly at
ages 1-or-2, 4, 10, and 18 years, the generalized estimating equations (GEE) method will
be used, which accounts for the correlated observations and the within-child effect by
employing a covariance matrix solved through an iterative estimating process based on a
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working correlation matrix [88]. The appropriate working correlation matrix will be
determined by using the Akaike information criterion (AIC).
In an explanatory step, to determine whether the RRs of the association of FLG
variants with asthma and rhinitis differ according to the presence or absences of the
proposed effect modifiers, we evaluated the association in the total study sample and subsamples based on the status of the possible effect modifiers. Next, interaction terms, on a
multiplicative scale, were used to test the additional effect of two co-occurring risk
factors on the health outcomes above and beyond their individual effects. Also, to
evaluate whether the effect of FLG variants across levels of the effect modifiers were
statistically significantly different, we included interaction terms in separate regression
models (model 1: FLG variants × eczema and model 2: FLG variants × allergic
sensitization). To decipher which interactive effect was more pronounced, a regression
model including both interaction terms (model 3: FLG variants × eczema and FLG
variants × allergic sensitization) was evaluated. Henceforth, we refer to models 1, 2, and
3 as the ‘concurrent models’ since the effect modifiers and the outcomes coexisted at the
same time. In the case of a possibly statistically significant interaction term (Pinteraction <
0.1), the “combined effect”, referring to the joint impact of two individual risk factors
plus their interaction on the occurrence of the outcome, was estimated as follows: RR =
exp[(β1 × allergic sensitization) + (β2 × FLG variants) + (β3 × allergic sensitization ×
FLG variants)]. We repeated the previous analyses while stratifying by sex to determine
if sex-specific effects existed. In all GEE models, sex and age at follow-up were included
as potential confounders.
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In addition to the concurrent models, we tested the interactions in ‘delayed effect’
models to investigate whether the time-order of risk and response supports the concurrent
model findings. The delayed effect analysis helps to determine whether the interaction
effects contribute to the developmental process of asthma and rhinitis. To this end, we
analyzed whether FLG variants interact with preceding allergic sensitization or eczema
on the risk of subsequent asthma and rhinitis. For example, the interaction of FLG
variants with allergic sensitization status at age 1-or-2 years on the risk of asthma at age 4
years (FLG variants × SPT results at 1-or-2 years  asthma at 4 years) was evaluated.
The prevalence of the clinical phenotype (e.g., asthma at 4), which was used in the
delayed effect models, included new occurrences and persistence of the disease.
Therefore, we constructed three delayed periods (1-or-2 to 4 years, 4 to 10 years, and 10
to 18 years) to determine if the presence of both FLG variants and preceding allergic
sensitization or preceding eczema influences the positive transition, defined as the change
in disease status from disease-free to diseased, and the persistence of the disease in two
consecutive follow-ups.

2.5.2 SPECIFIC AIM 2: STATISTICAL ANALYSIS
SA2: To test whether FLG variants and allergic sensitization jointly predispose to the
comorbidity of eczema, asthma and rhinitis (H3).
Information on eczema, asthma, and rhinitis were collected prospectively at ages
1-or-2, 4, 10, and 18 years from the IOW study participants. For each age I will create a
new variable that has 8 categories, which identifies all the possible combinations of
allergic comorbidities at the respective follow-up (Table 2.1). This type of categorization
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will allow us to have better understanding on the prevalence of each allergic category at
the different ages.
Table 2.1. Categories of allergic comorbidities
No Disease
Rhinitis
Asthma
Eczema
Eczema + Asthma
Eczema + Rhinitis
Asthma + Rhinitis
Eczema + Asthma + Rhinitis
To estimate the single and combined effects of the risk factors, FLG variants and
repeated measures of allergic sensitization, on allergic disorders, generalized estimating
equations (GEE) were used when estimating the covariance matrix to account for
correlated observations and the within-child effect of the repeated measurements [88].
Risk ratios (RR) and their 95% confidence intervals (95% CIs) were estimated by
applying log-binomial regression models using the GENMOD procedure in SAS 9.3
(SAS, Gary, NC, USA). The “no allergic disorder” category formed the reference
category. The main effects of FLG variants and allergic sensitization on the risk for
single allergic disorders and comorbidities were estimated separately (single risk factor
models). In a full model, the two main plus their interaction effect (FLG variants ×
allergic sensitization) were estimated. We repeated the aforementioned analysis while
excluding the 1-or-2 years follow-up data from the GEE analysis to estimate whether
possible misclassifications of phenotypes at early life biased our results. In the case of a
possibly statistically significant interaction (Pinteraction < 0.1), the combined effect was
estimated as follows: RR = exp[(β1 × allergic sensitization) + (β2 × FLG variants) + (β3
× allergic sensitization × FLG variants)]. The term ‘combined effect’ was used to
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describe the joint impact of two individual risk factors plus their interaction on the
occurrence of the outcome. In all GEE models, sex and age at follow-up were included as
potential confounders. To evaluate statistical significance of main effects of covariates
(not interaction terms), a P-value ≤ 0.05 was used as indicator of statistical significance.
To determine the proportion of the different allergic morbidities/comorbidities
related to FLG variants and allergic sensitization, population attributable fractions (PAFs)
were estimated using the following formula: PAF = pc × [(RR – 1)/RR], where pc is the
proportion of diseased-individuals that are exposed [89, 90]. This approach yields valid
PAF estimates in the presence of confounding and/or effect modification, only when
using adjusted RRs [89, 90]. In case of statistically significant interactions between
allergic sensitization and FLG variants, the RRs for the combined effect were used to
estimate PAFs associated with both risk factors. If no interaction was detected, adjusted
RRs were used to estimate separate PAFs for each of the two risk factors and an overall
PAF was obtained using the following formula: PAFoverall = 1 – [(1 – PAFallergic sensitization)
× (1 – PAFFLG variants)] [89].

2.5.3 SPECIFIC AIM 3: STATISTICAL ANALYSIS
SA3: To associate DNA methylation across the EDC genomic region with eczema status
(H4).
Although genome-wide DNA methylation profiles were available, I restricted the
analysis to 256 CpG sites that span the EDC genomic region (location on human
chromosome 1: 151958685 – 153628983). After performing quality control measures on
DNA methylation data, Beta-values presented as the proportion of methylated (M) over
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methylated (M) and unmethylated (U) sites (Beta-value = M/[c+M+U], with c being
constant to prevent dividing by zero) were calculated for each CpG site [87]. Beta-values
provide intuitive biological interpretation (i.e., % methylation); however, (i) being
constrained between values of 0 (unmethylated) and 1 (completely methylated) and (ii)
demonstrating high heteroscedasticity in the lower and upper ends of the methylation
range has raised concerns on the validity of this measure when performing statistical
analysis [91]. The conversion of Beta-values to M-values (M-value = log2(Beta-value/[1 –
Beta-value]) has been shown to overcome the limitations of beta-values [91]. Moreover,
the use of M-values, when performing statistical analysis, demonstrated increased
reliability in terms of detecting differentially methylated CpG sites; however, M-values
cannot be directly interpreted [91, 92]. Therefore, following previous recommendation
[91], we used M-values when performing the statistical analysis and reported the statistics
at the scale of Beta-values.
All statistical analyses were conducted using SAS® version 9.3 (SAS Institute,
Cary, NC, USA). In the discovery cohort, linear regression was used to test the
association between DNA methylation (M-values) of all CpG sites spanning the EDC
region with eczema status adjusting for sex and cell-type composition. To minimize
false-positive findings identified in 256 models, CpG sites with a false discovery rate
(FDR) adjusted p-value < 0.1 were selected and considered as potentially associated with
eczema. The selected CpG sites, in the discovery cohort, were taken forward and tested
for their possible association with eczema status in replication cohorts I and II. Then, the
selected CpG sites were tested for association with eczema in males and females
separately.
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CHAPTER 3
RESULTS I

MANUSCRIPT # 1: ASSOCIATION OF FILAGGRIN VARIANTS WITH ASTHMA AND RHINITIS: IS
ECZEMA OR ALLERGIC SENSITIZATION STATUS AN EFFECT MODIFIER?1

1

A. H. Ziyab, W. Karmaus, J. W. Holloway, H. Zhang, S. E. Steck, S. Ewart, S. H.
Arshad. Submitted to International Archives of Allergy and Immunology, 12/4/2013.
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3.1 ABSTRACT
Background: Association of filaggrin (FLG) variants with asthma and rhinitis have
shown to be modulated by eczema status. However, it is unknown whether allergic
sensitization status modifies this association. The aim of this study was to determine
whether FLG variants need eczema and/or allergic sensitization as a necessary
component to execute its adverse effect on coexisting and subsequent asthma and rhinitis.
Methods: Repeated measurements of asthma, rhinitis, eczema, and allergic sensitization
(documented by skin prick tests) at ages 1, 2, 4, 10, and 18 years were ascertained in the
Isle of Wight birth cohort (n = 1,456). FLG haploinsufficiency was defined as having at
least the minor allele of R501X, 2282del4, or S3247X variants. Log binomial regression
models were used to test associations and statistical interactions.
Results: FLG variants increased the risk of asthma (RR = 1.39, 95% CI: 1.06 – 1.80) and
rhinitis (RR = 1.37, 95% CI: 1.16 – 1.63). In delayed effect models, ‘FLG variants plus
allergic sensitization’ and ‘FLG variants plus eczema’ increased the risk of subsequent
asthma by 4.93-fold (95% CI: 3.61 – 6.71) and 3.33-fold (95% CI: 2.45 – 4.51),
respectively, during the first 18 years of life. In contrast, neither eczema nor allergic
sensitization in combination with FLG variants increased the risk of later rhinitis.
Conclusions: Allergic sensitization and eczema modulated the association between FLG
variants and asthma, but not rhinitis. Results of our study imply that the mechanisms and
pathways through which FLG variants predispose to increased risk of asthma and rhinitis
may be different.
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3.2 INTRODUCTION
The burden associated with allergic disorders, including eczema, asthma, and
rhinitis is substantial and of public health importance. Prior investigations indicated that a
complex interplay between genetic, immunological, and environmental factors
contributes to the development and maintenance of such allergic manifestations. Until
recently, etiologic research focused on the role of immune dysregulation in the
pathogenesis of allergic disorders; however, a shift in the research paradigm towards
understanding the contribution of a defective epidermal barrier rapidly emerged after the
discovery of loss-of-function variants in the filaggrin gene (FLG) [53, 56, 60]. Filaggrin
haploinsufficiency, defined as partial or complete loss of filaggrin (filament-aggregating
protein) protein, is associated with the development of an impaired epidermal barrier that
is characterized by increased allergen penetration and water permeability [93].
Thus far, FLG variants are the most replicated and strongest genetic risk factor for
eczema [59]. Also, FLG variants are considered to be associated with asthma and rhinitis
[66]. Of importance is that the association between FLG variants and asthma is stronger
in the presence of eczema [59, 66]. However, this possible effect modification by eczema
was not demonstrated for the association between FLG variants and rhinitis [66].
Mechanisms that underlie the association of FLG variants with asthma and rhinitis are
not well understood since FLG is not expressed in the upper or lower airway epithelium
[94, 95]. A proposed pathway is that cutaneous sensitization, facilitated by FLG variants,
may lead to local and systematic inflammation at distant organs (i.e., lung and nasal
tissues) [56, 60].
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While the concept that eczema leads to asthma in children who have a loss-offunction variants in the FLG gene is attractive, research in this area has neglected the role
of allergic sensitization, defined as the propensity to produce immunoglobulin E (IgE)
antibodies responses to environmental and food antigens [96]. Only one study based on
the German Multicenter Allergy Study (MAS) birth cohort addressed allergic
sensitization and reported an interaction between FLG variants and food sensitization in
the pathogenesis of asthma among children with eczema [97]. Hence, further
investigations on whether the associations of FLG variants with asthma and rhinitis are
modified by eczema and/or allergic sensitization are needed so that preventive efforts can
be directed to either clinical management of eczema or allergic sensitization or both.
We hypothesized that allergic sensitization, rather than eczema status, modifies
the association of FLG variants with asthma and rhinitis. Therefore, statistical
interactions (FLG variants × allergic sensitization and FLG variants × eczema) were
tested to determine whether FLG variants plus allergic sensitization and/or FLG variants
plus eczema jointly increased the risk of asthma and/or rhinitis. To this end, analyzing
longitudinal data from the Isle of Wight birth cohort covering childhood and adolescence
prospectively enabled us to determine whether FLG variants need allergic sensitization or
eczema as a necessary component to execute its adverse effect on coexisting and
subsequent asthma and rhinitis.
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3.3 METHODS
3.3.1 STUDY DESIGN AND PARTICIPANTS
An unselected whole population birth cohort (n = 1,536) was recruited in 1989 in
the Isle of Wight, UK, to prospectively study the natural history of allergic conditions.
After exclusion of adoptions, perinatal deaths, and refusal for follow-up, 1,456 (95%)
children were enrolled, with follow-up assessments conducted at 1, 2, 4, 10, and 18 years
of age. Ethics approvals were obtained from the Isle of Wight Local Research Ethics
Committee (NRES Committee South Central – Southampton B) at recruitment and for
the subsequent follow-ups (06/Q1701/34). At each follow-up, validated questionnaires,
including the International Study of Asthma and Allergy in Childhood (ISAAC)
questionnaire [4], were completed on allergic disorders plus demographic attributes and
exposures to environmental factors.

3.3.2 PHENOTYPES
In all assessments of the Isle of Wight birth cohort, eczema was defined as
chronic or chronically relapsing, itchy dermatitis lasting more than 6 weeks with
characteristic morphology and distribution [83], following Hanifin and Rajka criteria
[84]. For asthma, at the 1, 2, and 4-year follow-ups, the medical investigator determined
the presence of asthma based on wheeze frequency over the last 12 months and treatment
given for asthma or asthma related symptoms. At the 10 and 18 year follow-ups, asthma
was defined as having “ever had asthma” and either “wheezing or whistling in the chest
in the last 12 months” or “current treatment for asthma”, using ISAAC questionnaire [4].
Rhinitis was defined by a positive response to: ‘In the past 12 months have you had a
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problem with sneezing, or a runny or a blocked nose when you did not have a cold or the
flu?’ [33] Since the 1-year and 2-year follow-up data on eczema, asthma, and rhinitis
were collected in a relatively small time window, we combined them for analytic
purposes (reported as 1-or-2 years).
To determine allergic sensitization status, skin prick testing (SPT) at ages 1 and 2
years was performed on children with any symptoms of eczema, asthma, or rhinitis. We
combined SPT results for ages 1 and 2 years since they occurred within a short time
period and will henceforth refer to this as SPT at 1-or-2 years. At 4, 10, and 18 years,
regardless of symptoms, SPT was performed on most children attending the research
center to a standard battery of common allergens (ALK-Albello, Horsholm, Denmark).
Inhalant allergens tested were house dust mite, cat, dog, Alternaria alternata,
Cladosporium herbarium, grass pollen mix, and tree pollen mix. Food allergens tested
were cows’ milk, soya, hens’ egg, peanut and cod. Positive and negative controls were
included. Allergic sensitisation was defined by having a positive SPT to at least one
allergen test with mean wheal diameter of 3 mm greater than the negative control. Since
allergic sensitization is a dynamic rather than a completely stable phenotype, we used the
concurrent and/or preceding status and thus allowed the risk to change over time.

3.3.3 FLG GENOTYPING
Blood and/or saliva samples were collected at ages 10 and/or 18 years from which
genomic DNA was isolated. DNA samples were interrogated using GoldenGate
Genotyping Assays (Illumina, Inc, SanDiego, CA) on the BeadXpressVeracode platform
(Illumina, Inc, SanDiego, CA) per Illumina’s protocol. Individuals carrying the minor
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allele for at least one of the FLG variants R501X, 2282del4, or S3247X were classified as
having filaggrin haploinsufficiency. The R2447X variant was also genotyped, but none of
the study participants carried the minor allele. Detailed information on genotyping is
provided by Ziyab et al. [79].

3.3.4 STATISTICAL ANALYSIS
Since the proposed effect modifiers (i.e., allergic sensitization and eczema) and
the two outcomes (i.e., asthma and rhinitis) were measured repeatedly at ages 1-or-2, 4,
10, and 18 years, we applied the generalized estimating equation (GEE) method with
first-order autoregressive covariance matrix to account for the correlated observations
and the within-child effect of the repeated measurements [88]. Risk ratios (RR) and their
95% confidence intervals (95% CIs) were estimated by applying log-binomial regression
models using the GENMOD procedure in SAS 9.3 (SAS, Gary, NC, USA). To determine
whether the RRs of the association of FLG variants with asthma and rhinitis differ
according to the presence or absences of the proposed effect modifiers, we evaluated the
association in the total study sample and sub-samples based on the status of the possible
effect modifiers.
Interaction terms, on a multiplicative scale, were used to test the additional effect
of two co-occurring risk factors on the health outcomes above and beyond their
individual effects. Also, to evaluate whether the effect of FLG variants across levels of
the effect modifiers were statistically significantly different, we included interaction
terms in separate regression models (model 1: FLG variants × eczema and model 2: FLG
variants × allergic sensitization). To decipher which interactive effect was more
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pronounced, a regression model including both interaction terms (model 3: FLG variants
× eczema and FLG variants × allergic sensitization) was evaluated. Henceforth, we refer
to models 1, 2, and 3 as the ‘concurrent models’ since the effect modifiers and the
outcomes coexisted at the same time. In the case of a possibly statistically significant
interaction term (Pinteraction < 0.1), the “combined effect”, referring to the joint impact of
two individual risk factors plus their interaction on the occurrence of the outcome, was
estimated. We repeated the previous analyses while stratifying by sex to determine if sexspecific effects existed. In all GEE models, sex and age at follow-up were included as
potential confounders.
In addition to the concurrent models, we tested the interactions in ‘delayed effect’
models to investigate whether the time-order of risk and response supports the concurrent
model findings. The delayed effect analysis helps to determine whether the interaction
effects contribute to the developmental process of asthma and rhinitis. To this end, we
analyzed whether FLG variants interact with preceding allergic sensitization or eczema
on the risk of subsequent asthma and rhinitis. For example, the interaction of FLG
variants with allergic sensitization status at age 1-or-2 years on the risk of asthma at age 4
years (FLG variants × SPT results at 1-or-2 years  asthma at 4 years) was evaluated.
The prevalence of the clinical phenotype (e.g., asthma at 4), which was used in the
delayed effect models, included new occurrences and persistence of the disease.
Therefore, we constructed three delayed periods (1-or-2 to 4 years, 4 to 10 years, and 10
to 18 years) to determine if the presence of both FLG variants and preceding allergic
sensitization or preceding eczema influences the positive transition, defined as the change
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in disease status from disease-free to diseased, and the persistence of the disease in two
consecutive follow-ups [37].

3.4 RESULTS
3.4.1 DESCRIPTION OF STUDY POPULATION
Of the 1,456 children enrolled in the study, 1,377 were followed-up at age 1-or-2
years, 1,214 at 4 years, 1,368 at 10 years, and 1,309 at 18 years. The period prevalence
ranged between 11.9% to 14.2% for eczema, 14.3% to 17.7% for asthma, and 5.6% to
35.8% for rhinitis (table 3.1). At age 1-or-2 years, SPTs were performed on symptomatic
children (n = 515), of which 20.6% had at least one positive SPT response. At all other
ages, the majority of participates underwent SPTs with the proportion of positive SPTs
being 19.4% at 4 years, 26.9% at 10 years, and 41.4% at 18 years of age. Genotype
frequencies of FLG variants (table 3.1) were concordant with Hardy-Weinberg
equilibrium.

3.4.2 FLG VARIANTS AND ASTHMA
In the total study sample, FLG variants increased the risk of repeated occurrence
of asthma from 1-or-2 to 18 years of age (RR = 1.39, 95% CI: 1.06 – 1.80; figure 3.1). In
the presence of eczema, the effect size increased (RR = 1.56, 95% CI: 1.10 – 2.21); in the
absence of eczema, the magnitude of the association between FLG variants and asthma
was reduced and lost statistical significance (RR = 1.26, 95% CI: 0.93 – 1.69). This
association was noticeably modified when stratifying based on the presence (RR = 1.49,
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95% CI: 1.14 – 1.94) or absence (RR = 0.76, 95% CI: 0.48 – 1.21) of allergic
sensitization.
To determine whether the observed differences in the associations were
statistically significant, statistical interactions on a multiplicative scale were evaluated in
concurrent models. There was no evidence for an interaction between FLG variants and
eczema on the risk for asthma (interaction effect RR = 1.18, 95% CI: 0.78 – 1.79,
Pinteraction = 0.429; figure 3.1). However, a statistically significant interaction was found
between FLG variants and allergic sensitization on the risk for asthma (interaction effect
RR = 2.00, 95% CI: 1.22 – 3.28, Pinteraction = 0.006; figure 3.1). The combined effect of
FLG variants and allergic sensitization increased the risk of asthma by 3.63-fold (95%
CI: 2.81 – 4.70). Furthermore, to determine which interactive effect is more important,
we simultaneously included both interaction terms in one regression model. Results
showed that the interaction between FLG variants and allergic sensitization remained
statistically significant after adjusting for the interactive effect between FLG variants and
eczema (data not shown). However, the latter did not gain statistical significance.
We retested the results of the aforementioned concurrent models, using delayed
effect models. In these models we used the preceding cumulative SPTs results (or eczema
status), i.e. all SPTs results (or eczema status) from assessments that are prior to the
outcome assessment, when testing the interaction between FLG variants and allergic
sensitization (or eczema) on the risk of subsequent asthma. The results of the delayed
effect models show that the combined effect of preceding allergic sensitization with FLG
variants increased the risk of asthma in the next exam at each delay period (figure 3.2a).
For instance, the presence of both FLG variants plus positive SPT at 1-or-2 and/or 4 years
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increased the risk of asthma at 10 years (RR = 7.22, 95% CI: 4.84 – 10.80). Although
results of the concurrent model (figure 3.1) did not show an interaction between FLG
variants and eczema, the delayed effect models demonstrated interactive effects between
FLG variants and preceding eczema on the risk of subsequent asthma (figure 3.2b). The
repeated measurement analysis shows that the combined effect of FLG variants and
preceding eczema, on average, increased the risk of later asthma during the first 18 years
of life (RR = 3.33, 95% CI: 2.45 – 4.51).
To further understand whether the observed interactions between FLG variants
and preceding allergic sensitization and eczema influence new occurrence and/or
persistence of asthma, we calculated the proportions of positive transitions (defined as the
change in disease status from disease-free to diseased in two consecutive follow-ups) and
persistence among those with and without both risk factors (table 3.2). The proportion of
positive transition was more frequent among those with FLG variants and allergic
sensitization as compared to those without both risk factors across all transition periods.
For instance, in the presence of both FLG variants and allergic sensitization, 5/16
(31.3%) of those without asthma at age 4 years developed asthma at age 10 years;
whereas, only 23/532 (4.3%) of those without both risk factors developed asthma at 10
years. Furthermore, the presence of both risk factors influenced the persistence of asthma
(table 3.2). For example, 18/21 (85.7%) of participants with both risk factors who had
asthma at ages 10 years continued to have asthma at 18 years, as compared to 25/44
(56.8%) among those without the two risk factors. Similarly, the presence of both FLG
variants and preceding eczema influenced the positive transition and persistence of
asthma.
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3.4.3 FLG VARIANTS AND RHINITIS
FLG variants were associated with increased risk for rhinitis from age 1-or-2 to
18 years in the total study sample of repeated measurements (RR = 1.37, 95% CI: 1.16 –
1.63; figure 3.3). In both the presence (RR = 1.57, 95% CI: 1.23 – 2.00) and absence (RR
= 1.28, 95% CI: 1.04 – 1.57) of eczema, the association between FLG variants and
rhinitis was statistically significant. However, we observed a statistically significant
association between FLG variants and rhinitis only in the presence of allergic
sensitization (RR = 1.34, 95% CI: 1.17 – 1.53), and not in its absence (RR = 1.13, 95%
CI: 0.82 – 1.55; figure 3.3).
To test if the observed heterogeneous effects across the levels of the potential
effect modifiers are statistically different, we tested multiplicative statistical interactions
in concurrent models. There was no evidence for an interactive effect neither between
FLG variants and eczema (interaction effect RR = 1.15, 95% CI: 0.83 – 1.60, Pinteraction =
0.409; figure 3.3) nor between FLG variants and allergic sensitization (interaction effect
RR = 1.07, 95% CI: 0.76 – 1.51, Pinteraction = 0.698; figure 3.3) on the risk for rhinitis.
Concordant with results of concurrent models, the delayed effect models did not show
any interactions between FLG variants and preceding allergic sensitization or eczema on
the risk of subsequent rhinitis (figure 3.4).

3.4.4 SEX DIFFERENCES AND TIME TRENDS
Separate analyses for each sex were performed and the results for boys and girls
were similar (data not shown) and in agreement with the results of analyzing both sexes
together in the repeated measurement (GEE) analysis. Furthermore, at each follow-up we
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analyzed boys and girls separately to determine whether the effects differ across both
time and sex. The obtained results indicated that neither age of exam nor sex influenced
our results.

3.5 DISCUSSION
The objective of this study was to determine whether eczema and/or allergic
sensitization status act as effect modifiers for the association of FLG variants with asthma
and rhinitis. In this study, FLG variants increased the risk of asthma and rhinitis during
the first 18 years of life in the total study sample. In concurrent effect models, interaction
between FLG variants and allergic sensitization resulted in a combined effect that
increased the risk of coexisting asthma by 3.63-fold. Delayed effect models, which take
the time order of risk factors and disease occurrences into account, supported the findings
of the concurrent effect models regarding allergic sensitization and FLG variants. In
addition, the delayed effect models showed that FLG variants interact with preceding
eczema status on the development of subsequent asthma, indicating that both allergic
sensitization and eczema act as effect modifiers for the association between FLG variants
and asthma. In contrast, neither eczema nor allergic sensitization modified the association
of FLG variants with rhinitis in a statistically significant manner.
The association between FLG variants and asthma among those with eczema was
first reported by Palmer et al. [53]. Subsequently, several studies have replicated this
association and added a possible association between FLG variants and rhinitis [59, 66].
Results of our study further support the general agreement that FLG variants are
associated with asthma in the presence of eczema. We further demonstrated that both
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preceding allergic sensitization and eczema modified the association between FLG
variant and asthma through multiplicative interaction (figure 3.2). These findings indicate
that FLG variants need eczema or allergic sensitization to execute their adverse effects on
asthma. The finding of an interaction between FLG variants and allergic sensitization in
this study improves our understanding of the possible link between genetics of the
epidermal barrier (i.e., FLG variants) and a respiratory disorder (i.e., asthma). Such an
observation further supports the hypothesis that cutaneous sensitization priming,
facilitated by FLG variants, may migrate to the airways and cause local and systematic
inflammation [98]. Although prior studies have widely suggested such a pathway, the
majority of previous investigations did not take the status of allergic sensitization into
account. An exception is the study by Marenholz et al., which showed an interaction
between FLG variants and food sensitization on the risk of asthma in children with
eczema [97], however, their analytical sample was restricted to children with eczema.
In the delayed effect models we used the prevalence of asthma as the outcome,
which does not distinguish between new occurrences and persistence of asthma.
Therefore, in additional descriptive analysis, we demonstrated that the presence of both
FLG variants and preceding allergic sensitization or preceding eczema influenced the
new occurrences (positive transition) and persistence of asthma. Hence, our data suggest
that the presence of both risk factors (‘FLG variants and preceding allergic sensitization’
or ‘FLG variants and preceding eczema’) plays an important role in the development and
persistence of asthma.
Attempts using the composite of ‘atopic asthma’ phenotype were conducted to
investigate whether allergic sensitization is the link between FLG variants and asthma.
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Inconsistent results for the association of FLG variants with ‘atopic asthma’ have been
reported [62, 64, 99, 100]. These inconsistencies could be attributed to the use of the
composite ‘atopic asthma’ phenotype, which does not clearly define the reference (no
risk) group. By taking this approach investigators tend to group ‘non-atopic asthmatics’
and ‘atopics without asthma’ participants together in the reference group. Therefore,
when assessing the association of FLG variants with ‘atopic asthma’ one should be aware
that the reference group could include atopic participants, which could result in distorting
assessments. The advantage of our approach, using two separate risk factors, over the
composite ‘atopic asthma’ phenotyping, is that we were able to estimate the additional
effect due to interaction (FLG variants × allergic sensitization) that is above and beyond
their independent effects. Hence, allowing us to determine whether the combined effect
of both risk factors is more than just the multiplication of their independent effects.
There is conflicting evidence in the literature as to whether the association
between FLG variants and rhinitis is modulated by eczema status. The majority of
previous studies found a stronger association between FLG variants and rhinitis in the
presence of coexisting eczema when compared to their association in the absence of
concurrent eczema [62, 63, 65, 66, 101]. Another investigation reported an association
between FLG variants and ‘persistent allergic rhinitis’ phenotype [99]. Controversially,
however, a significant association has also been reported between FLG variants and the
composite ‘allergic rhinitis’ phenotype adjusted for eczema status [64]. Our analyses did
not reveal interaction between eczema (Pinteraction = 0.409) or allergic sensitization
(Pinteraction = 0.698) with FLG variants on the risk of rhinitis in the repeated measurement
analysis. Our results of an interactive effect between FLG variants and allergic
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sensitization on the risk of asthma and the lack of such interaction on the risk of rhinitis
suggest that the pathway through which FLG variants predispose to asthma and rhinitis
may be different. For instance, the expression of filaggrin protein was not detected in the
human bronchial epithelium; however, it has been shown that filaggrin is expressed in the
nasal vestibule [64, 94]. That said, the extent to which filaggrin expression in the nasal
vestibular lining influence the development of rhinitis is yet to be investigated by future
studies.
Major strengths of our prospective, 18-year study are the repeated phenotyping,
objective assessments of allergic sensitization status, and the low loss to follow-up
(ranged from 5% to 17%). Moreover, the majority (80%) of the study participants were
genotyped for FLG variants common among populations of European ancestry [57]. We
showed, previously, that the genotyped study participants did not differ from the total
cohort with regard to multiple characteristics [79]. Hence, there is no indication of
selection bias that could pose a threat to the validity of our study. Misclassification of
eczema cases is minimal since a high proportion of subjects showed typical manifestation
of eczema in the usual locations (antecubital or popliteal fossae, ankles, face or neck for
97% at 1 year, 91% at 2 years, 75% at 4 years, 86% at 10 years and 76% at 18 years)
[25].
Potential limitations are the definition of asthma and rhinitis symptoms in early
life. Our asthma conclusion at ages 10 and 18 years followed the ISAAC criteria [4],
which was at that time not available for assessments at age 1, 2, and 4 years. Although
slightly different methods were used to define asthma, in a previous report we have
shown that the minor change in asthma definition over time did not influence the validity
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of our asthma classification [37]. In addition, since it is difficult to differentiate between
infectious and other forms of rhinitis in infancy, the elevated prevalence at 1-or-2 years
might have been influenced by misclassifying ‘viral induced infectious rhinitis’ [33].
However, by applying repeated measurements analysis including assessments later in
childhood and adolescence, we believe that the influence of the possible misclassification
of rhinitis at 1-or-2 years on the overall results of the study is minimal, since similar
results were obtained when we reran our analyses excluding the 1-or-2 year data.
Moreover, since SPTs at age 1-or-2 years were performed on symptomatic children, we
speculate that selection bias leading to underestimated RRs might have been induced.
Although proportions of SPT positivity at ages 1-or-2 years (20.6%) and 4 years (19.6%;
SPT performed irrespective of symptoms) were similar, RRs associating allergic
sensitization at age 1-or-2 years with outcomes (i.e., eczema, asthma, and rhinitis) at the
same age tended to be smaller than RRs relating allergic sensitization at age 4 years with
outcomes at the same age (data not shown), since also the reference group had some
symptoms. Hence, the estimated RRs at age 1-or-2 might be underestimated; however,
the extent of the possible selection bias is minimal since our results did not noticeably
change when we excluded the 1-or-2 years follow-up data from the analyses. Such
observations further demonstrate the robustness of the GEE method in providing
population averaged estimates (RRs) while accounting for the within-subject correlations
of repeated measurements. The use of a slightly relaxed statistical significance threshold
(PInteraction < 0.1) for detecting interaction-effects is further supported by the fact that
majority of epidemiologic studies lack sufficient power to detect higher order-terms
[102].
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In conclusion, our results indicate that allergic sensitization and eczema status are
effect modifiers of the association between FLG variants and asthma. The combined
effects of ‘preceding allergic sensitization and FLG variants’ and ‘preceding eczema and
FLG variants’ increased the risk of subsequent asthma by 4.93-fold and 3.33-fold,
respectively, during the first 18 years of life. These findings suggest that FLG variants
need allergic sensitization or eczema to execute its adverse effects on asthma. In contrast,
neither eczema nor allergic sensitization status statistically significantly modulated the
association between FLG variants and rhinitis. Hence, results of our study suggest that
the mechanisms and pathways through which FLG variants, representing impaired
epidermal barrier, predispose to increased risk of asthma and rhinitis may be different.
Future studies confirming our reported observations and exploring the differential
etiological pathways underlying the development of asthma and rhinitis are needed to
better identify and stratify those who share similar risk characteristics.
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Figure 3.1. Concurrent association of FLG variants with asthma in total study sample
and sub-samples: longitudinal analysis covering 1-or-2 to 18 years of age. The prevalence
of asthma among those with filaggrin loss-of-function (FLG LOF) variants and those
with wild-type genotype (FLG WT) is shown. RR: Risk ratio; 95% CI: 95% confidence
interval; k= number of repeated measurements.
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Figure. 3.2. a) Delayed effect models exploring the individual and combined effects of FLG variants and
preceding allergic sensitization status on asthma development. Independent effects of FLG variants (SPT & FLG LOF), positive SPT (SPT + & FLG WT), and their combined effect (SPT + & FLG LOF) in the
development of asthma are shown for different ages. We modeled the effect of preceding SPT results on
later asthma. b) Delayed effect models exploring the individual and combined effects of FLG variants and
preceding eczema status on asthma development. Independent effects of FLG variants (Eczema - & FLG
LOF), eczema (Eczema + & FLG WT), and their combined effect (Eczema + & FLG LOF) in the
development of asthma are shown for different ages. We modeled the effect of preceding eczema results on
later asthma. SPT +: positive SPT, SPT -: negative SPT; Eczema +: positive eczema diagnosis, Eczema -:
negative eczema diagnosis; FLG LOF: filaggrin loss-of-function; FLG WT: filaggrin wild-type genotype; n
= number of children; k= number of repeated measurements. The asterisk (*) and the double dagger (‡)
indicate that the interaction effect (a: SPT × FLG; b: Eczema × FLG) is possibly statistically significantly
different from the null value of 1 (*: PInteraction < 0.1; ‡: PInteraction < 0.05); suggesting interaction on
multiplicative scale. The dagger (†) indicates that the risk estimate (RR) of the given column is statistically
significantly (P < 0.05) different from the column without both risk factors (a: SPT - & FLG WT; b:
Eczema & FLG WT). The presence of both an asterisk (*) or double dagger (‡) and dagger (†) signifies
that the combined effect of the two risk factors is above and beyond their individuals effects.
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Figure 3.3. Concurrent association of FLG variants with rhinitis in total study sample
and sub-samples: longitudinal analysis covering 1-or-2 to 18 years of age. The prevalence
of rhinitis among those with filaggrin loss-of-function (FLG LOF) variants and those
with wild-type genotype (FLG WT) is shown. RR: Risk ratio; 95% CI: 95% confidence
interval; k= number of repeated measurements.
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Figure 3.4. a) Delayed effect models exploring the individual and combined effects of FLG variants and
preceding allergic sensitization status on rhinitis development. Independent effects of FLG variants (SPT & FLG LOF), positive SPT (SPT + & FLG WT), and their combined effect (SPT + & FLG LOF) in the
development of rhinitis are shown for different ages. We modeled the effect of preceding SPT results on
later rhinitis. b) Delayed effect models exploring the individual and combined effects of FLG variants and
preceding eczema status on rhinitis development. Independent effects of FLG variants (Eczema - & FLG
LOF), eczema (Eczema + & FLG WT), and their combined effect (Eczema + & FLG LOF) in the
development of rhinitis are shown for different ages. We modeled the effect of preceding eczema results on
later rhinitis. SPT +: positive SPT, SPT -: negative SPT; Eczema +: positive eczema diagnosis, Eczema -:
negative eczema diagnosis; FLG LOF: filaggrin loss-of-function; FLG WT: filaggrin wild-type genotype; n
= number of children; k= number of repeated measurements. The dagger (†) indicates that the risk estimate
(RR) of the given column is statistically significantly (P < 0.05) different from the column without both
risk factors (a: SPT - & FLG WT; b: Eczema & FLG WT).
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Table 3.1. Characteristics of study population
Attributes
% (n/total)
Sex
Male
51.2 (786/1536)
Eczema at
1-or-2 years
4 years
10 years
18 years

14.2 (196/1377)
11.9 (145/1214)
13.7 (186/1359)
12.3 (161/1307)

Asthma at
1-or-2 years
4 years
10 years
18 years

14.3 (197/1377)
14.9 (181/1214)
14.7 (201/1368)
17.7 (231/1305)

Rhinitis at
1-or-2 years
4 years
10 years
18 years

15.8 (217/1377)
5.6 (65/1214)
22.6 (308/1362)
35.8 (468/1309)

FLG variants*
R501X
2282del4
S3247X
Combined

4.1 (47/1161)
4.6 (54/1168)
1.6 (18/1165)
10.3 (118/1150)

Allergic sensitization† at
1-or-2 years
20.6 (106/515)
4 years
19.6 (192/982)
10 years
26.9 (279/1036)
18 years
41.4 (353/853)
*
Analyses were conducted using the combined carrier frequency of 10.3%.
†
Presence of allergic sensitization was defined by having on or more positive skin prick
test result at the respective assessment.
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Table 3.2. Prevalence, positive transition, and persistence of asthma stratified based on
FLG variants and preceding allergic sensitization and eczema status: comparing
proportions of those with both risk factors to those without the risk factors
Asthma % (n/total)
Prevalence

Age 4 years

Age 10 years

Age 18 years

FLG WT & SPT –

18.4 (57/310)

7.9 (47/595)

10.3 (62/604)

FLG LOF & SPT +

50.0 (9/18)

60.0 (18/30)

54.8 (23/42)

p-value

0.003

< 0.001

< 0.001

FLG WT & Eczema –

11.9 (86/725)

11.2 (91/811)

16.0 (118/739)

FLG LOF & Eczema +

52.0 (5/6)

51.5 (17/33)

51.3 (20/39)

p-value

< 0.001

< 0.001

< 0.001

Positive transition†

1-or-2 to 4 years

4 to 10 years

10 to 18 years

FLG WT & SPT –

8.5 (19/223)

4.3 (23/532)

6.7 (37/550)

FLG LOF & SPT +

50.0 (6/12)

31.3 (5/16)

23.8 (5/21)

p-value

< 0.001

< 0.001

0.014

FLG WT & Eczema –

8.5 (53/635)

7.0 (44/632)

9.3 (59/639)

FLG LOF & Eczema +

42.1 (8/19))

29.4 (5/17)

14.3 (3/21)

p-value

< 0.001

0.006

0.437

Persistence‡

1-or-2 to 4 years

4 to 10 years

10 to 18 years

FLG WT & SPT –

43.7 (38/87)

38.7 (24/62)

56.8 (25/44)

FLG LOF & SPT +

50.0 (3/6)

92.9 (13/14)

85.7 (18/21)

p-value*

0.542

< 0.001

0.026

FLG WT & Eczema –

36.7 (33/90)

44.7 (38/85)

68.3 (56/82)

FLG LOF & Eczema +

83.3 (5/6)

80.0 (12/15)

94.4 (17/18)

0.031

0.023

0.037

*

*

*

*

*

p-value

FLG LOF: filaggrin loss-of-function; FLG WT: filaggrin wild-type genotype; SPT -: negative skin prick
test result; SPT +: positive skin prick test result.
*
p-values comparing the proportions across the two exposure groups were derived from fisher’s exact test.
†
Positive transition refers to the change in disease status from asthma-free to asthma in two consecutive
assessments.
‡
Persistence refers to the proportion of individuals who had asthma at two consecutive assessments
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CHAPTER 4
RESULTS II

MANUSCRIPT # 2: ALLERGIC SENSITIZATION AND FILAGGRIN VARIANTS PREDISPOSE TO
THE COMORBIDITY OF ECZEMA, ASTHMA, AND RHINITIS: RESULTS FROM THE ISLE OF

WIGHT BIRTH COHORT2
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permission of publisher.
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4.1 ABSTRACT
Background: Allergic sensitization and filaggrin gene (FLG) variants are important risk
factors for allergic disorders; however, knowledge on their individual and interactive
effects on the coexistence of eczema, asthma, and rhinitis is lacking.
Objective: This study aimed at investigating the single and combined effects of allergic
sensitization and FLG variants on the development of single and multiple allergic
disorders.
Methods: The Isle of Wight Birth Cohort (n = 1,456) has been examined at 1, 2, 4, 10,
and 18 years of age. Repeated measurements of eczema, asthma, rhinitis, and skin prick
tests were available for all follow-ups. FLG variants were genotyped in 1,150
participants. Associations of allergic sensitization and FLG variants with single and
multiple allergic disorders were tested in log-binomial regression analysis.
Results: The prevalence of eczema-, asthma-, and rhinitis-only ranged from 5.6% to
8.5%, 4.9% to 10.2%, and 2.5% to 20.4%, respectively, during the first 18 years of life.
The coexistence of allergic disorders is common, with approximately 2% of the
population reporting the comorbidity of “eczema, asthma, and rhinitis” during the study
period. In repeated measurement analyses, allergic sensitization and FLG variants, when
analyzed separately, were associated with having single and multiple allergic disorders.
Of particular significance, their combined effect increased the risk of “eczema and
asthma” (RR = 13.67, 95% CI: 7.35 – 25.42), “asthma and rhinitis” (RR = 7.46, 95% CI:
5.07 – 10.98), and “eczema, asthma, and rhinitis” (RR = 23.44, 95% CI: 12.27 – 44.78).
Conclusions and Clinical Relevance: The coexistence of allergic disorders is frequent
and allergic sensitization and FLG variants jointly increased risk of allergic
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comorbidities, which may represent more severe and complex clinical phenotypes. The
interactive effect and the elevated proportion of allergic comorbidities associated with
allergic sensitization and FLG variants emphasize their joint importance in the
pathogenesis of allergic disorders.

4.2 INTRODUCTION
Allergic disorders, including eczema, asthma, and rhinitis, pose social and
economic burden on individuals, families, and societies [1, 2]. Worldwide, the lifetime
prevalence of eczema symptoms (e.g., itchy rash) is estimated to be 15% to 30% among
children and 2% to 10% among adults [19]. Similarly, the prevalence of asthma (up to
25%) and rhinitis (up to 30%) is high [16, 29, 32]. Natural history investigations have
demonstrated close and complex relationships between these allergic disorders [25, 33,
48, 103-105]. However, mechanisms and pathways underlying their development is an
area of ongoing scientific dispute.
The “allergic march” concept suggests that allergic disorders develop in a
sequential pattern, starting with eczema in early infancy and later in childhood
developing asthma and rhinitis [106]. However, supporting replicable evidence and
consensus is far from complete [42, 107, 108]. An opposing concept is the “coexistence”
of allergic morbidities [42, 45, 109]. A report based on the German Multicenter Allergy
Study showed that single occurrence of eczema early in life does not result in an allergic
march, but the coexistence of eczema and wheezing predicted asthma [45]. Results from
the BAMSE birth cohort showed that the comorbidity of allergic disorders is frequent
during the first 12 years of life [109]. Such observations speak in favor of coexistence of
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allergic morbidities instead of a progressive development. The interrelationship between
these conditions and the risk factors that predispose individuals to develop multiple
allergic disorders is an open field for research.
Interplay between genetic, environmental, and immunological factors is
considered to contribute to the pathogenesis of allergic disorders [110]. Allergic
sensitization, defined as the susceptibility to produce immunoglobulin E (IgE) antibodies
in response to antigens, is widely-considered as a common thread linking various
manifestations of allergic disorders [49, 96]. Likewise, loss-of-function variants in the
filaggrin gene (FLG) resulting in an impaired epidermal barrier have rapidly emerged as
common risk factor for the development of allergic disorders [60]. However, there is a
gap in understanding of the respective contribution of FLG variants and allergic
sensitization on the development of allergic comorbidities. Moreover, the joint role of
FLG variants and allergic sensitization on the coexistence of eczema, asthma, and rhinitis
has not been previously investigated. Using data from the Isle of Wight (IOW) birth
cohort, we aimed at determining the single and combined effects of FLG variants and
allergic sensitization on the development of single and multiple (coexisting) allergic
disorders.

4.3 MATERIALS AND METHODS
4.3.1 STUDY DESIGN AND PARTICIPANTS
An unselected whole population birth cohort (n = 1,536) was recruited in 1989 on
the Isle of Wight, UK, to prospectively study the natural history of allergic conditions.
After exclusion of adoptions, perinatal deaths, and refusal for follow-up, written informed
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consent was obtained from parents to enroll 1,456 (95%) newborns, with follow-up
assessments conducted at 1, 2, 4, 10, and 18 years of age. Ethics approvals were obtained
from the Isle of Wight Local Research Ethics Committee (now named the National
Research Ethics Service, NRES Committee South Central – Southampton B) at
recruitment and for the subsequent follow-ups (06/Q1701/34).

4.3.2 PHENOTYPES
In all assessments of the IOW birth cohort, eczema was defined as chronic or
chronically relapsing, itchy dermatitis lasting more than 6 weeks with characteristic
morphology and distribution [83], following Hanifin and Rajka criteria [84]. For asthma,
at the 1, 2, and 4-year follow-ups, the medical investigator determined the presence of
asthma based on wheeze over the last 12 months and treatment given for asthma or
asthma related symptoms. At the 10 and 18 year follow-ups, asthma was defined as
having “ever had asthma” and either “wheezing or whistling in the chest in the last 12
months” or “current treatment for asthma”, following the International Study of Asthma
and Allergies in Childhood (ISAAC) criteria [4]. Rhinitis was defined by a problem with
sneezing, or a runny or a blocked nose without a cold or the flu in the last 12 months
[33]. Since the 1-year and 2-year follow-up data were collected in a relatively small time
window, we combined them for analytic purposes (reported as 1-or-2 years).
To determine allergic sensitization, skin prick tests (SPTs) at ages 1 and 2 years
were performed on children with any symptoms of eczema, asthma, or rhinitis. Parallel to
the disorders, we combined the SPTs at ages 1 and 2 years (reported as 1-or-2 years). At
4, 10, and 18 years, regardless of symptoms, SPTs were performed on most children
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attending the research center using 14 common food and aeroallergens (ALK-Albello,
Horsholm, Denmark) [111]. Allergic sensitization was defined by having a positive SPT
to at least one test with mean wheal diameter of 3 mm greater than the negative control.
Since allergic sensitization is a dynamic phenotype, we used the concurrent status and
thus allowed the risk to change over time.

4.3.3 FLG GENOTYPING
Blood and/or saliva samples were collected at ages 10 and/or 18 years from which
genomic DNA was isolated. DNA samples were interrogated using GoldenGate
Genotyping Assays on the BeadXpressVeracode platform (Illumina, Inc, SanDiego, CA)
per Illumina’s protocol. Individuals carrying the minor allele for at least one of the FLG
variants R501X, 2282del4, or S3247X were classified as having filaggrin
haploinsufficiency. Detailed information on genotyping is provided by Ziyab et al [79].

4.3.4 STATISTICAL ANALYSIS
The 12-month period prevalence of eczema, asthma, rhinitis, and their
comorbidities combinations was determined for each follow-up. Combinations of three
disorders resulted in eight non-overlapping comorbidities groups (Table 4.1). To estimate
the single and combined effects of the risk factors, FLG variants and repeated measures
of allergic sensitization, on allergic disorders, generalized estimating equations (GEE)
were used when estimating the covariance matrix to account for correlated observations
and the within-child effect of the repeated measurements [88]. Risk ratios (RR) and their
95% confidence intervals (95% CIs) were estimated by applying log-binomial regression
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models using the GENMOD procedure in SAS 9.3 (SAS, Gary, NC, USA). The “no
allergic disorder” category formed the reference category. The main effects of FLG
variants and allergic sensitization on the risk for single allergic disorders and
comorbidities were estimated separately (single risk factor models). In a full model, the
two main plus their interaction effect (FLG variants × allergic sensitization) were
estimated. We repeated the aforementioned analysis while excluding the 1-or-2 years
follow-up data from the GEE analysis to estimate whether possible misclassifications of
phenotypes at early life biased our results. In the case of a possibly statistically
significant interaction (Pinteraction < 0.1), the combined effect was estimated as follows: RR
= exp[(β1 × allergic sensitization) + (β2 × FLG variants) + (β3 × [allergic sensitization ×
FLG variants])]. The term ‘combined effect’ was used to describe the joint impact of two
individual risk factors plus their interaction on the occurrence of the outcome. In all GEE
models, sex and age at follow-up were included as potential confounders. To evaluate
statistical significance of main effects of covariates (not interaction terms), a P value ≤
0.05 was used as indicator of statistical significance.
Population attributable fractions (PAFs), defined as the proportion of disease that
can be related to a specific risk factor(s) [89], were estimated using the following
formula: PAF = pc × [(RR – 1)/RR], where pc is the proportion of diseased-individuals
that are exposed [89, 90]. This approach yields valid PAF estimates in the presence of
confounding and/or effect modification, only when using adjusted RRs [89, 90]. In case
of statistically significant interactions between allergic sensitization and FLG variants,
the RRs for the combined effect were used to estimate PAFs associated with both risk
factors. If no interaction was detected, adjusted RRs were used to estimate separate PAFs
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for each of the two risk factors and an overall PAF was obtained using the following
formula: PAFoverall = 1 – [(1 – PAFallergic sensitization) × (1 – PAFFLG variants)] [89].

4.4 RESULTS
A total of 1,377, 1,210, 1,345, and 1,298 children, out of 1,456, had available
information on eczema, asthma, and rhinitis diagnosis at ages 1-or-2, 4, 10, and 18 years,
respectively (Table 4.1). SPT results were available for 515 (age 1-or-2: only children
with any symptoms), 982, 1,036, and 853 children at ages 1-or-2, 4, 10, and 18 years,
respectively. The proportion of positive SPTs increased from 20.6% to 41.4% between
ages 1-or-2 and 18 years. Although SPT at age 1-or-2 was performed only on
symptomatic children, the proportion of sensitized children at ages 1-or-2 and 4 years
were similar (20.6% vs. 19.6%). The combined proportion of carriers (heterozygous) of
FLG variants R501X, 2282del4 and S3247X was 10.3% (118/1150; Table 4.1).

4.4.1 PREVALENCE OF ALLERGIC DISORDERS
The period prevalence of “eczema only” was between 7.9% and 8.5% during the
first 10 years of life and decreased to 5.6% at 18 years of age (Table 4.1). “Asthma only”
was most prevalent (10.2%) at 4 years. The period prevalence of “rhinitis only”, despite
the drop at age 4, demonstrated an increasing trend over time by reaching 20.4% at 18
years of age. The comorbidity of “eczema and asthma” and “eczema and rhinitis” ranged
from 0.6% to 2.4% and 0.6% to 3.6%, respectively, between 1-or-2 and 18 years. Having
“asthma and rhinitis” was most common (9.0%) at age 18 years. A coexistence of
eczema, asthma, and rhinitis was found in approximately 2% over the study period.
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4.4.2 ASSOCIATION ANALYSIS: SINGLE RISK FACTOR MODELS
FLG variants showed increased risk of “eczema only” (RR = 1.37, P = 0.101) and
“rhinitis only” (RR = 1.27, P = 0.064; Table 4.2) that was not statistically significance,
during the first 18 years of life. However, FLG variants predisposed to increased risk of
having “eczema + asthma” (RR = 2.41, P < 0.01), “asthma + rhinitis” (RR = 1.52, P <
0.01), and a trend for increased risk of “eczema + rhinitis” (RR = 1.69, P = 0.077).
Moreover, the risk of “eczema, asthma, and rhinitis” was 3.43 fold-higher among those
with FLG haploinsufficiency than those with functional FLG gene. Accordingly, FLG
variants showed stronger associations with allergic comorbidities than single disorders.
Allergic sensitization, statistically significantly, increased the risk of “eczema-“,
“asthma-“, and “rhinitis-only” by 1.70-, 2.50-, 2.76-fold over the study period (Table
4.2). In addition, allergic sensitization predisposed to increased risk of having “eczema +
asthma” (RR = 6.64, P < 0.01), “eczema + rhinitis” (RR = 3.48, P < 0.01), and “asthma +
rhinitis” (RR = 4.71, P < 0.01). In particular, allergic sensitization was associated with an
increased risk for the coexistence of “eczema, asthma, and rhinitis” (RR = 9.22, P <
0.01).

4.4.3 ASSOCIATION ANALYSIS: TWO RISK FACTORS MODELS
Simultaneously adjusting for FLG variants and allergic sensitization plus their
interaction effect allowed us to determine their individual and combined effects. In these
adjusted models, FLG variants did not show any association with allergic disorders
(Table 4.3). In contrast, allergic sensitization was significantly associated with all allergic
disorders. FLG variants and allergic sensitization showed possible interactive effects for
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three of the studied comorbidities. Combined effect of allergic sensitization and FLG
variants increased the risk of “eczema and asthma” (RR = 13.67, P < 0.01), “asthma and
rhinitis” (RR = 7.46, P < 0.01), “eczema, asthma, and rhinitis” (RR = 23.44, P < 0.01;
Table 4.3). To estimate whether the possible misclassifications of rhinitis/asthma at age
1-or-2 years influenced our results, we repeated the previous analyses while excluding
data from the 1-or-2 years. Comparable results were obtained when we repeated our
analysis by only including data from 4, 10, and 18 years follow-ups in the GEE analysis
(data not shown).

4.4.4 SEX DIFFERENCES
To determine whether sex is a potential effect modifier, we ran separate models
for boys and girls. The effects of FLG variants and allergic sensitization on the risk of
having single and multiple morbidities were similar for boys and girls. For instance, FLG
variants associated with 2.95-fold (95% CI: 1.35 – 6.42, P < 0.01) higher risk of having
‘eczema + asthma + rhinitis’ among boys; whereas, a 3.97-fold (95% CI: 1.96 – 8.05, P <
0.01) higher risk was observed among girls (Pinteraction for sex = 0.597; detailed data not
shown).

4.4.5 POPULATION ATTRIBUTABLE FRACTIONS (PAFS)
PAFs related to FLG variants and allergic sensitizations were estimated for the
different allergic disorders using adjusted RRs from Table 4.3. A larger fraction of
allergic disorders in the population can be related to allergic sensitization than to FLG
variants, when simultaneously adjusting for their effects (Table 4.4). Around 13.7% to
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29.5% of single allergic disorders might be related to having both allergic sensitization
and FLG variants. High PAFs for having “eczema, asthma, and rhinitis” (49%), “eczema
+ asthma” (33.7%), and “asthma + rhinitis” (21.2) were related to the combined effect of
both allergic sensitization and FLG variants.

4.5 DISCUSSION
In this well-characterized longitudinal study, allergic comorbidities were
prevalent at all ages. For the first time, we assessed the single and combined effects of
FLG variants and allergic sensitization on the development of single allergic disorders
and comorbidities. FLG variants, when adjusting for the effect of allergic sensitization,
did not show any association with allergic disorders. Against that, allergic sensitization,
adjusting for the effect of FLG variants, increased the risk of all allergic disorders.
Substantial combined effects of both factors were detected for allergic comorbidities. For
instance, a 23-fold increased risk for having “eczema, asthma, and rhinitis”
(approximately 2% of the cohort) was associated with the presence of both FLG variants
and allergic sensitization.
Investigating and understanding the role of deviated immune responses, i.e.
allergic sensitization, in the atopic diathesis have dominated the research field. However,
the discovery of FLG variants and their pronounced role in the development of allergic
disorders, eczema in particular, has caused a shift in the research paradigm toward
understanding the contribution of dysfunctional skin barrier. FLG variants are considered
to result in a compromised epidermal barrier that is characterized by increased
penetration of allergens and microbes and elevated transepidermal water loss [60]. In

58

eczema, the role of FLG variants is well established; however, since FLG is not
expressed in the respiratory epithelia its contribution to the development of allergic
disorders of the airways is not clear [56, 60]. A suggested pathway is that cutaneous
sensitization, facilitated by FLG variants, could lead to local and systematic inflammation
at distant organs (i.e., lung and nasal tissues) [56]. Also the contrary is of importance,
since it has been shown that inflammatory Th2 cytokines can also alter the integrity of
the skin barrier, even in the absence of genetic variants that disrupt its integrity and
function [112]. Hence, the two competing views: “inside-outside” which suggests that
immunologic abnormality is the initiating and triggering step in the pathogenesis of
allergic disorders and the “outside-inside” which posits that a defective epidermal barrier
is the driver with epiphenomenal immunological sequelae, seem to be plausible and to
some extent interdependent [77]. Therefore, simultaneously considering the contribution
of genetic predisposition toward a defective skin barrier (i.e., FLG variants) and the
propensity for immune dysregulation (i.e., allergic sensitization) could provide new and
improved insights into the etiopathogenesis of allergic disorders.
Previous studies showed that FLG variants increased the risk of eczema and
predisposed to higher risk of asthma and rhinitis only in the presence of coexisting
eczema [59, 66]. Hence, suggesting that FLG variants increase the risk of allergic
comorbidities, such as ‘asthma plus eczema’ and ‘rhinitis plus eczema’. Our results
further support and add to the previously reported findings. However, we showed that
FLG variants did not pose any increased risk of single and multiple allergic disorders
while controlling for the effect of allergic sensitization. But, significant interactive effects
of both risk factors were associated with increased risk of allergic comorbidities.
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Although previous investigations inconsistently showed that FLG variants increased the
risk of allergic sensitization [65, 66, 99], we did only observe a weak association between
FLG variants and allergic sensitization in this cohort [79]. The possibility of an
association between FLG variants and allergic sensitization cannot be totally excluded;
however, since only around 15% of those with allergic sensitization carry FLG variants in
our cohort, we speculate that any possible indirect effect of FLG variants on allergic
diseases that goes through allergic sensitization to be minimal. Moreover, the possibility
of non-independence between the two factors, also known as gene-environment
correlation, might bias the interactive effects [113]. Due to the weak non-significant
association between FLG variants and allergic sensitization in our cohort, we have little
concern that the unlikely non-independence of the two factors might bias the observed
interactive effects. In support of our analytical model, we clearly demonstrated in a
previous report that FLG variants posed no increased risk of eczema in the absences of
allergic sensitization, whereas, allergic sensitization increased the risk of eczema
independent of FLG variants and the combined effect of both factors led to elevated risk
above and beyond their individual effects [79]. Similarly, Wang et al. showed that the
association between FLG variants and eczema was limited to a subset of children with
IgE levels ≥ 100 kU/L [114]. Hence, we suggest considering the combined effect of both
risk factors rather than taking the cause-effect approach could lead to a better risk
assessment.
Our estimated PAFs suggested that approximately 21% to 49% of allergic
comorbidities in the population may be attributed to the presence of both FLG variants
and allergic sensitization. In agreement with results of this report, it has been shown that
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a large proportion (38%) of allergic comorbidities can be explained by allergic
sensitization alone [115]. Although, the contribution of FLG variants to the overall PAFs
seems to be limited while controlling for the main effect of allergic sensitization, the
PAFs associated with the combined effects of both risk factors (i.e., in the presence of
possible interactive effects between FLG variants and allergic sensitization) is
substantial. Our results suggest that FLG variants need allergic sensitization as a
necessary component to execute its adverse effect. Therefore, early identification of those
who are genetically predisposed to a dysfunctional skin barrier and who have increased
allergic sensitization propensity may expedite the success of intervention/prevention
efforts and measures.
The etiologic approach taken so far by research in the field of FLG variants and
allergic disorders has substantially improved our understanding of these multifactorial
disorders. However, as suggested by Ballardini et al., allergic disorders should not be
studied as single entities [109], rather investigating their coexistence could assess in
identifying shared underlying risk factors. Hence, we considered all possible and nonoverlapping combinations of eczema, asthma, and rhinitis. Through this approach we
were able to show that FLG variants increased the risk of allergic comorbidities rather
than single disorders, suggesting its contribution towards a more severe and complex
clinical phenotype. The effect of FLG variants when combined with the effect of allergic
sensitization predisposed to even higher risk of allergic comorbidities. In contrast to
investigating the coexistence of allergic disorders, evidence supporting the progression of
events (i.e., allergic march) also exists [116, 117]. For instance, a valid assumption is that
eczema predisposes to allergic sensitization, which in turn predicts asthma and rhinitis.
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However, evidence supporting both pathways exists: (i) eczema precedes allergic
sensitization and (ii) allergic sensitization precedes eczema [118, 119]. In the context of
FLG variants, we have demonstrated, previously, that the combined effect of FLG
variants and allergic sensitization predisposed to increased risk of subsequent eczema
[79]. Also, we showed that the combination of FLG variants and eczema (FLG variants
alone does not) increased the risk of subsequent allergic sensitization, which was limited
to the first 10 years of life. Taken together, these observations suggest that multiple
pathways could underlie the development of allergic disorders. Therefore, the
development of allergic disorders is more complex and do not necessarily follow the
atopic march paradigm. Although our approach does not take into account the sequence
of the individual allergic manifestations, results of this report demonstrated that the comanifestation of allergic disorders is common and FLG variants and allergic sensitization
are common risk factors.
Major strengths of our study are the repeated phenotyping and the low attrition
(ranging from 5% to 17%). FLG variants genotypes were available for the majority
(80%) of the study population. Previously, we demonstrated that the genotyped sample
did not differ from the total cohort with respect to multiple characteristics [79]. Although
skin prick tests were performed at the different follow-ups to determine sensitization
status, not measuring specific IgE is a limitation to our study. Moreover, since SPTs at
ages 1 and 2 years were performed on symptomatic children, we speculate that selection
bias leading to underestimated RRs might have been induced. Although proportions of
SPT positivity at ages 1-or-2 years (20.6%) and 4 years (19.6%; SPT performed
irrespective of symptoms) were similar, RRs associating allergic sensitization at age 1-or-
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2 years with outcomes (i.e., eczema, asthma, and rhinitis) at the same age tended to be
smaller than RRs relating allergic sensitization at age 4 years with outcomes at the same
age (data not shown), since also the reference group had some symptoms. Hence, the
estimated RRs at age 1-or-2 might be biased; however, the extent of the possible
selection bias is minimal since our results did not noticeably change when we excluded
the 1-or-2 years follow-up data from the analyses. Such observations further demonstrate
the robustness of the GEE method in providing population averaged estimates (RRs)
while accounting for the within-subject correlations of repeated measurements.
Misclassification of eczema cases is minimal since a high proportion of subjects showed
typical manifestation of eczema in usual locations (antecubital or popliteal fossae, ankles,
face or neck for 97% at 1 year, 91% at 2 years, 75% at 4 years, 86% at 10 years and 76%
at 18 years) [25]. In addition, the prevalence of eczema in our cohort (13.7% at age 10
years and 12.3% at age 18 years) is comparable to results from ISAAC studies conducted
among children aged 13–14 years in the United Kingdom (UK) (14.7% phase one and
10.6% phase three) and other studies conducted in the UK [5, 120, 121].Other, potential
limitations are the definition of asthma and rhinitis symptoms in early life. Our asthma
conclusion at ages 10 and 18 years followed the ISAAC criteria [4], which was at that
time not available for assessments at ages 1, 2, and 4 years. Although slightly different
methods were used to define asthma; however, in a previous report we demonstrated that
the minor change in asthma definition did not influence the validity of our asthma
classification [37]. In addition, since it is difficult to differentiate between infectious and
other forms of rhinitis in infancy, the elevated prevalence at 1-or-2 years (6.5% vs. 2.5%
at age 4 years) might have been influenced by misclassifying ‘viral induced infectious
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rhinitis’ [33]. The influence of the possible misclassification of rhinitis at 1-or-2 years on
the overall results of the study is minimal since similar results were obtained when we
reran our analyses while excluding the 1-or-2 year data.
In conclusion, comorbidities of eczema, asthma, and rhinitis are prevalent and
both allergic sensitization and FLG variants are common risk factors that predispose to
the comorbidity of allergic disorders. The combination of both risk factors was associated
with elevated risk of coexisting allergic manifestations. Approximately 21% to 49% of
the comorbidities in the population are related to both allergic sensitization and FLG
variants. The coexistence of allergic disorders might reflect more severe clinical
phenotypes that require more and longer medical care. However, investigations of
comorbidities and their underlying etiological risk factors are limited. Therefore,
additional etiological investigations regarding allergic comorbidities are recommended,
as this will allow for a better phenotypic characterization.
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Table 4.1. Characteristics of the Isle of Wight study population at different ages
Follow-up at age
1-or-2 years
4 years
10 years
% (n)
n = 1377
n = 1210
n = 1345
Sex
Male
50.8 (700)
51.1 (618)
50.7 (682)

18 years
n = 1298
49.6 (644)

68.9 (949)
8.5 (117)
4.9 (68)
6.5 (89)
1.9 (26)
1.8 (25)
5.5 (75)
2.0 (28)

74.1 (897)
7.9 (96)
10.2 (123)
2.5 (30)
2.4 (29)
0.6 (7)
1.3 (16)
1.0 (12)

61.8 (832)
8.0 (107)
6.3 (84)
13.4 (181)
1.0 (14)
2.4 (32)
4.7 (63)
2.4 (32)

52.7 (684)
5.6 (73)
5.5 (71)
20.4 (265)
0.6 (7)
3.6 (47)
9.0 (117)
2.6 (34)

Allergic sensitization
≥ 1 positive SPT

n = 515
20.6 (106)

n = 982
19.6 (192)

n = 1036
26.9 (279)

n = 853
41.4 (353)
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No allergic disorders
Eczema only
Asthma only
Rhinitis only
Eczema + asthma
Eczema + rhinitis
Asthma + rhinitis
Eczema + asthma + rhinitis

FLG variants*
n = 1150
Yes
10.3 (118)
SPT: Skin prick test
*
FLG variants were present in 118 participants of the 1150 who were genotyped. The prevalence of FLG variants changes based on
the analytical sample.

Table 4.2. Single risk factor models: associations of FLG variants and allergic sensitization with allergic conditions: longitudinal
analysis from age 1-or-2 to 18 years

No allergic disorders (Ref.), % (k)
Eczema only, % (k)
RR (95% CI)

Single risk factor model: FLG
variants*
FLG variants genotype
WT (k = 3831)$
LOF (k = 442)$
64.2 (2459)
54.3 (240)
7.6 (291)
8.8 (39)
1.00
1.37 (0.94 – 1.99)

Single risk factor model: Allergic
sensitization*
Allergic sensitization
SPT – (k = 2453)$
SPT + (k = 929)$
65.3 (1602)
29.7 (276)
9.5 (234)
9.8 (91)
1.00
1.70 (1.36 – 2.12)‡
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Asthma only, % (k)
6.6 (253)
6.1 (27)
7.2 (177)
9.7 (90)
RR (95% CI)
1.00
1.07 (0.71 – 1.61)
1.00
2.50 (1.99 – 3.14)‡
Rhinitis only, % (k)
11.2 (428)
12.4 (55)
10.0 (246)
20.8 (193)
RR (95% CI)
1.00
1.27 (0.99 – 1.64)
1.00
2.76 (2.34 – 3.27)‡
Eczema + asthma, % (k)
1.4 (52)
2.9 (13)
1.1 (27)
4.1 (38)
RR (95% CI)
1.00
2.41 (1.28 – 4.57)‡
1.00
6.64 (4.18 – 10.54)‡
Eczema + rhinitis, % (k)
2.0 (76)
2.7 (12)
2.1 (52)
4.2 (39)
RR (95% CI)
1.00
1.69 (0.95 – 3.02)
1.00
3.48 (2.35 – 5.18)‡
Asthma + rhinitis, % (k)
5.4 (205)
6.8 (30)
3.7 (90)
15.1 (140)
†
RR (95% CI)
1.00
1.52 (1.04 – 2.23)
1.00
4.72 (3.76 – 5.94)‡
Eczema + asthma + rhinitis, % (k) 1.8 (67)
5.9 (26)
1.0 (25)
6.7 (62)
RR (95% CI)
1.00
3.43 (2.02 – 5.83)‡
1.00
9.22 (5.63 – 15.12)‡
WT: Wild-type; LOF: Loss-of-function; SPT – : Negative skin prick test; SPT +: Positive skin prick test; Ref.: represent the common reference category; k:
refers to the total number of repeated measurements.
*
In all GEE models sex and age at follow-up were included as potential confounders.
$
The presented numbers in parenthesis (k = ) refer to the number of repeated measurements. See Table 4.1 for more information on the number of individuals.
†
P-value < 0.05
‡
P-value < 0.01

Table 4.3. Two risk factors model: associations of FLG variants and allergic sensitization with allergic conditions: longitudinal
analysis from age 1-or-2 to 18 years
Two risk factors model: FLG variants and allergic sensitization*
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No allergic disorders (Ref.), % (k)
Eczema only, % (k)
RR (95% CI)
Asthma only, % (k)
RR (95% CI)
Rhinitis only, % (k)
RR (95% CI)
Eczema + asthma, % (k)
RR (95% CI)
Eczema + rhinitis, % (k)
RR (95% CI)

FLG variants genotype
WT (k = 2707)$
LOF (k = 328)$

Allergic sensitization
SPT – (k = 2164)$
SPT + (k = 871)$

RRInteraction
(PInteraction)#

56.9 (1540)
9.3 (252)
1.00
7.6 (205)
1.00
13.3 (360)
1.00
1.6 (44)
1.00
2.5 (68)
1.00

66.1 (1431)
9.2 (200)
1.00
6.7 (144)
1.00
10.4 (226)
1.00
1.0 (22)
1.00
2.1 (46)
1.00

0.98
(0.961)
1.05
(0.926)
0.85
(0.538)
5.46
(0.016)
1.48
(0.511)

46.3 (152)
10.1 (33)
1.11 (0.81 – 1.54)
6.4 (21)
0.99 (0.65 – 1.53)
14.6 (48)
1.21 (0.95 – 1.55)
4.0 (13)
0.49 (0.08 – 3.03)
3.4 (11)
1.52 (0.85 – 2.69)

30.0 (261)
9.8 (85)
1.74 (1.38 – 2.19)‡
9.4 (82)
2.65 (2.07 – 3.39)‡
20.9 (182)
2.68 (2.25 – 3.19)‡
4.0 (35)
5.12 (2.95 – 8.90)‡
3.8 (33)
3.19 (2.09 – 4.89)‡

Combined effect†

13.67 (7.35 – 25.42)‡

Asthma + rhinitis, % (k)
6.7 (182)
8.2 (27)
3.4 (73)
15.6 (136)
2.04
RR (95% CI)
1.00
0.79 (0.34 – 1.89) 1.00
4.57 (3.52 – 5.93)‡
7.46 (5.07 – 10.98)‡
(0.070)
Eczema + asthma + rhinitis, % (k) 2.1 (56)
7.0 (23)
1.0 (22)
6.5 (57)
3.59
‡
RR (95% CI)
1.00
1.02 (0.25 – 4.16) 1.00
6.43 (3.62 – 11.42)
23.44 (12.27 – 44.78)‡
(0.053)
WT: Wild-type; LOF: Loss-of-function; SPT – : Negative skin prick test; SPT +: Positive skin prick test; Ref.: represent the common reference category; k:
refers to the total number of repeated measurements; RRInteraction: Risk ratio associated with the interaction term.
*
In all GEE models sex and age at follow-up were included as potential confounders.
#
P-value < 0.1 was used to indicate presence of possible statistical interaction. If there was no evidence of interaction, the interaction term was removed from the
regression model and only the main effects were modeled.
$
The presented numbers in parenthesis (k = ) refer to the number of repeated measurements. See Table 4.1 for more information on the number of individuals.
†
Combined effect was estimated only in the presence of possibly statistically significant interaction term (FLG variants × allergic sensitization; PInteraction < 0.1).
‡
P-value < 0.01.

Table 4.4. Population attributable fractions of different allergic conditions related to FLG
variants and allergic sensitization
FLG variants Allergic sensitization
Overall
*
*
PAF† (%)
PAF (%)
PAF (%)
Eczema only
1.2
12.7
13.7
‡
Asthma only
n/a
22.6
22.6¶
Rhinitis only
2.1
28.0
29.5
$
$
Eczema + asthma
n/a
n/a
33.7
Eczema + rhinitis
4.8
28.7
32.1
$
$
Asthma + rhinitis
n/a
n/a
21.2
Eczema + asthma + rhinitis
n/a$
n/a$
49.0
PAF: population attributable fraction; n/a: not available
*
PAFs were estimated using adjusted risk ratios obtained from Table 4.3.
†
In the presence of statistically significant interaction, overall PAF were estimated using
the RR for the combined effect obtained from Table 4.3.
‡
PAF was not estimated due to RR < 1.00.
$
PAF was not estimated due to the presence of possible statistical interaction (see Table
4.3).
¶
This value represents the PAF associated with allergic sensitization only since PAF
associated with FLG variants was not estimable.
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CHAPTER 5
RESULTS III

MANUSCRIPT # 3: DNA METHYLATION OF THE EPIDERMAL DIFFERENTIATION COMPLEX IN
RELATION TO ECZEMA STATUS: AN EXPLORATORY STUDY3

3

A. H. Ziyab, W. Karmaus, J. W. Holloway, H. Zhang, S. E. Steck, S. Ewart, S. H.
Arshad. To be submitted to Journal of European Academy of Dermatology and
Venereology.
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5.1 ABSTRACT
Background: Genetic variants within genes located across the epidermal differentiation
complex (EDC) genomic region have shown associations with eczema risk. However,
knowledge on the role of epigenetic mechanisms (e.g., DNA methylation) within the
EDC locus on eczema risk is lacking.
Objective: To evaluate associations between DNA methylation of CpG sites across the
EDC genomic region with eczema status.
Methods: DNA methylation levels of 256 CpG sites spanning the EDC locus were
measured using Illumina's 450K array in three semi-independent cohorts; a subsample of
the Isle of Wight birth cohort (n = 367 participants aged 18 years, discovery cohort),
replication cohort I (n = 146; parents of the F2 generation), and replication cohort II (n =
94; F2 generation). Associations between eczema status and DNA methylation were first
assessed in the discovery cohort using linear regression. Methylation sites showing an
association with eczema in the discovery cohort at a false discovery rate p-value < 0.1
were taken forward for replication.
Results: Differential DNA methylation of CpG site cg12048339 (located within
promoter of S100A6 gene) was associated with eczema specifically among female
participants of all study cohorts; whereas, aberrant DNA methylation of cg10959711
(located within promoter of S100A11 gene) associated with eczema among male
participants in all study samples.
Conclusion: This exploratory study demonstrated that DNA methylation of the EDC
genomic region could be an important factor in the development of eczema in a sexspecific manner. Future studies corroborating our findings are needed.
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5.2 INTRODUCTION
The elevated life-time prevalence of eczema among children (up to 30%) and
adults (up to 10%) makes eczema a global public-health burden [22]. Immunologic
dysregulation and defective epidermal barrier are the main hallmarks of eczema [46]. In
last decades, etiologic research have focused on immune-related factors, including
genetics of immune system, in the pathogenesis of eczema; however, the discovery, in
2006, of loss-of-function variants in the filaggrin gene (FLG) have caused a shift in the
research paradigm towards understanding factors that regulate the formation and integrity
of the epidermal barrier [53, 68]. Filaggrin haploinsufficiency, defined as partial or
complete loss of filaggrin (filament-aggregating protein) protein, is associated with the
development of an impaired epidermal barrier that is characterized by increased
penetration of environmental substances and elevated transepidermal water loss [93]. As
yet, FLG variants are the strongest and most replicated genetic risk factors for eczema
development [59].
The FLG gene is located within a dense cluster of genes encoding structural and
regulatory proteins that are essential for keratinocyte differentiation, known as the
epidermal differentiation complex (EDC) [76, 81, 82]. The EDC locus, spanning 2 Mb on
human chromosomal region 1q21, harbors around 60 genes encoding loricrin and
involucrin proteins and gene-family clusters encoding: (i) small proline-rich (SPRR) and
late cornified envelope (LCE) proteins, (ii) calcium-binding proteins (S100A), and (iii)
S100-fused type proteins (SFTP) [76, 81, 82]. Apart from FLG variants, a limited number
of studies identified variants in other genes within the EDC that are associated with
eczema. For instance, conflicting results as to whether polymorphisms in the hornerin
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gene (HRNR), located 78 kb from FLG gene, are associated with eczema risk have been
reported [122, 123]. Regarding SPRR3, Marenholz et al. showed that a 24-bp deletion in
the gene was associated with eczema [124]. However, Stemmler et al. did not find
evidence of association between eczema and other EDC genetic variants than FLG
variants [125]. Both, genome-wide linkage and association studies have detected signals
of linkage/association between eczema and the EDC genomic locus [122, 126-128].
Morar et al. showed that the genetic linkage of eczema to the EDC region (LOD score =
3.57) was not totally diminished after accounting for FLG variants (LOD score = 2.03)
[129]. Hence, this finding point towards the presence of other genetic variants within the
EDC that influence eczema development. On the other hand, the limited success, apart
from FLG variants, of associating EDC gene variants with eczema is not promising.
Moreover, candidate-gene and genome-wide association studies have only explained a
small proportion of the high heritability (up to 85%) and clustering of eczema within
families [68, 69].
Epigenetic mechanisms (e.g., DNA methylation) may offer a complementary
explanation when considering the role of EDC on eczema. DNA methylation addresses
heritable genetic regulatory elements that alter gene activity (e.g., expression) without
changing the underlying nucleotide sequence of the DNA [130] have been speculated as
plausible predisposing factors in the development of eczema and might as well account
for the unexplained genetic effects [69]. Currently, there is a lack of knowledge on the
role of epigenetic mechanisms, in particular DNA methylation, of the EDC genomic
locus in relation to eczema risk. Therefore, a comprehensive DNA methylation profiling
of the EDC genomic region could further add understanding for this genomic region in
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development of eczema. To this end, in an EDC-wide screening this explorative study
aimed to evaluate the association of DNA methylation across the EDC region with
eczema status in participants of the Isle of Wight birth cohort (aged 18 years, F1
generation). The analyses further test any significant findings identified in the screening
(discovery) in two semi-independent samples (pregnant cohort participant, their partners,
and their offspring, the F2 generation).

5.3 MATERIALS AND METHODS
5.3.1 PARTICIPANTS AND CHARACTERISTICS
The Isle of Wight birth (IOW) cohort, an unselected population-based study, was
recruited between January 1989 and February 1990 in the Isle of Wight, UK, to study the
natural history and etiology of allergic diseases. After exclusion of adoptions, perinatal
deaths, and refusal for follow-up, 1,456 children (95%) were enrolled, with follow-up
assessments conducted at 1, 2, 4, 10, and 18 years of age. Ethics approvals were obtained
from the Isle of Wight Local Research Ethics Committee at recruitment and for the
subsequent follow-ups (06/Q1701/34). Written informed consent was obtained from
parents, participants, or both. In this analysis, the discovery cohort is based on a
subsample (n = 367, aged 18 years) of the IOW cohort that was randomly selected for
epigenetic study (Figure 5.1). We consider two cohorts to test the reproducibility of the
screening. Replication cohort I (n = 146; parents of the F2 generation) includes
participants of the IOW cohort (28.8% were part of the discovery cohort) plus new
participants. Expecting mothers and their partners were assessed before delivery.
Replication cohort II (n = 94; F2 generation) includes the F2 newborns of the IOW
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cohort participants (Figure 5.1). Infants were followed-up at ages 3-, 6-, and 12-months.
In all study samples, eczema was defined as chronic or chronically relapsing, itchy
dermatitis lasting more than 6 weeks with characteristic morphology and distribution,
following Hanifin and Rajka criteria [84].

5.3.2 DNA METHYLATION PROFILING
For the discovery cohort, DNA was extracted from whole blood collected at age
18 years using a standard salting out procedure [85], and bisulfite-treated for cytosine to
thymine conversion using the EZ 96-DNA methylation kit (Zymo Research, CA, USA).
Similarly, whole blood of replication cohort I participants’ and cord blood of replication
cohort II participants’ were collected and DNA was extracted and bisulfite converted
following the aforementioned standard procedures. In all samples, Genome-wide DNA
methylation was assessed using the Illumina Infinium HumanMethylation450 BeadChip
(Illumina, Inc., CA, USA), which interrogates > 484,000 CpG sites associated with
approximately 24,000 genes. For the purpose of this report, we restricted our analysis to
256 CpG sites that span the EDC genomic region (location on human chromosome 1:
151958685 – 153628983). Arrays were processed using a standard protocol [86], with
multiple identical control samples assigned to each bisulfite conversion batch to assess
assay variability and samples randomly distributed on microarrays to control against
batch effects [131]. The BeadChips were scanned using a BeadStation, and the
methylation level calculated for each queried CpG locus (cytosine-guanine dinucleotides)
using the Methylation Module of BeadStudio software. We used the DNA methylation
profiles of our participants to predict their cell-type composition via a method proposed
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by Houseman et al. [132] and validated by Koestler et al. [133]. This method identified
CpG loci from our data which were within differentially methylated regions (DMRs)
known to distinguish between white blood cell types, then utilized our Beta-values to
predict the proportions of CD8+ T-cells, CD4+ T-cells, natural killer cells, B-cells,
monocytes and granulocytes for each sample.

5.3.3 STATISTICAL ANALYSIS
After performing quality control measures on DNA methylation data, Beta-values
presented as the proportion of methylated (M) over methylated (M) and unmethylated (U)
sites (Beta-value = M/[c+M+U], with c being constant to prevent dividing by zero) were
calculated for each CpG site [87]. Beta-values provide intuitive biological interpretation
(i.e., % methylation); however, (i) being constrained between values of 0 (unmethylated)
and 1 (completely methylated) and (ii) demonstrating high heteroscedasticity in the lower
and upper ends of the methylation range has raised concerns on the validity of this
measure when performing statistical analysis [91]. The conversion of Beta-values to Mvalues (M-value = log2(Beta-value/[1 – Beta-value]) has been shown to overcome the
limitations of beta-values [91]. Moreover, the use of M-values, when performing
statistical analysis, demonstrated increased reliability in terms of detecting differentially
methylated CpG sites; however, M-values cannot be directly interpreted [91, 92].
Therefore, following previous recommendation [91], we used M-values when performing
the statistical analysis and reported the statistics at the scale of Beta-values.
All statistical analyses were conducted using SAS® version 9.3 (SAS Institute,
Cary, NC, USA). In the discovery cohort, linear regression was used to test the
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association between DNA methylation (M-values) of all CpG sites spanning the EDC
region with eczema status adjusting for sex and cell-type composition. To minimize
false-positive findings identified in 256 models, CpG sites with a false discovery rate
(FDR) adjusted p-value < 0.1 were selected and considered as potentially associated with
eczema. The selected CpG sites, in the discovery cohort, were taken forward and tested
for their possible association with eczema status in replication cohorts I and II. Then, the
selected CpG sites were tested for association with eczema in males and females
separately.

5.4 RESULTS
The 12-month period prevalence of eczema was 12.6%, 15.6%, and 16.7% in the
discovery cohort, replication cohort I, and replication cohort II, respectively (Table 5.1).
The period prevalence of eczema was statistically significantly higher among women
compared to men in the discovery cohort (15.2% vs. 7.4%, p-value = 0.034) and
replication cohort I (21.1% vs. 5.9%, p-value = 0.017). In contrast, eczema was more
common among infant boys (21.1%) in comparison with infant girls (11.8%) in
replication cohort II.
Epigenome-wide DNA methylation profiling, covering more than 484,000 CpG
sites across the genome, was performed in all three study samples. We restricted our
analysis to 256 CpG sites that spanned the EDC genomic region. In the discovery cohort,
screening for possible associations between DNA methylation of CpG sites within the
EDC and eczema identified five CpG sites that are differentially methylated between
eczema-affected and eczema-free participants with FDR adjusted p-values < 0.1 (Table
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5.2). The five identified CpG sites were then tested in women and men participants
separately. The sex-specific results showed that DNA methylation of the five CpG sites
was statistically significantly associated with eczema in women but not in men (Table
5.2). However, the directions of the effect sizes of three out of the five CpG sites
(cg10959711, cg13493250, and cg01910639) were in agreement between women and
men. For instance, DNA methylation at cg13493250 locus (located within the LCE1F
gene promoter region) was, on average, 4% higher in women and by 3% in men, when
comparing eczema-affect to eczema-free participants.
The five identified CpG sites were further tested for association with eczema in
replication cohort I (Table 5.3). None of the CpG sites showed statistically significant
association with eczema. The direction of the effect size of two CpG sites (cg10959711
and cg12048339) was in agreement when comparing results of the discovery cohort
(Table 5.2) with results of replication cohort I (Table 5.3). The sex-stratified analyses
showed DNA methylation of two CpG sites in females (cg10959711 and cg12048339)
and four CpG sites in males (cg10959711, cg13493250, cg03969260, and cg12048339)
were in agreement, in regard to effect size direction, between the discovery cohort and
replication cohort I.
Finally, associations between the five CpG sites and eczema were tested in the
replication cohort II (Table 5.4). In regard to statistical significance, none of the
associations were replicated; however, two CpG sites (cg10959711 and cg12048339)
showed similar magnitude of association as seen in the discovery cohort. In infant girls,
DNA methylation of one CpG site (cg12048339) demonstrated similar effect across the
discovery cohort and replication cohort II. In infant boys, DNA methylation of two CpG
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sites (cg10959711 and cg01910639) showed similar effects across the discovery cohort
and replication cohort II.
In the analysis that considered both sexes, there were two CpG sites (cg10959711
and cg12048339) that showed agreement in respect to the magnitude of their effect sizes
across the three study samples. Furthermore, inspecting the sex-specific analyses showed
that one CpG site (cg12048339) among female participants and one CpG site among
male participants (cg10959711) demonstrated similar effect sizes across the three study
samples. For instance, DNA methylation of cg12048339 was 2% (discovery cohort and
replication cohort I) and 1% (replication cohort II) lower in eczema-affected as
compared to eczema-free female participants. On the other hand, DNA methylation of
cg10959711 locus was 1% (discovery cohort and replication cohort I) and 3%
(replication cohort II) higher in eczema-affected as compared to eczema-free male
participants.

5.5 DISCUSSION
This explorative study, for the first time, investigated the possible association
between DNA methylation across the EDC genomic region with eczema in three semiindependent population based samples. In the discovery cohort, DNA methylation of five
CpG sites was associated with eczema status. Although results of replicating these
associations did not demonstrate statistical significance, two CpG sites (cg10959711 and
cg12048339) showed similar effect sizes across the three study samples. Noticeably,
DNA methylation of CpG site cg12048339 was associated with eczema specifically
among female participants of all study cohorts; whereas, DNA methylation of
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cg10959711 associated with eczema among male participants in all study samples. Such
results might point towards sex-specific associations between DNA methylation across
the EDC locus and eczema. Moreover, DNA methylation within the EDC genomic region
might explain some of the genome-wide linkage and association signals that relate the
EDC locus with eczema.
Both of the identified sex-specific CpG sites are located within genes that belong
to the S100A gene-family cluster on the EDC locus. The cg12048339 is located within
the promoter region of S100A6 gene, specifically 1500 base-pairs upstream of
transcription start site (TSS1500). Similarly, the cg10959711 is located within the
TSS1500 genomic region of S100A11 gene. The S100A genes, overall, share similar gene
structure by containing two introns and three exons (exon-2 and exon-3 are translated)
and encode proteins that, in general, contain two calcium-binding EF-hand motifs [134,
135]. The S100A proteins are involved in various biological functions and processes,
such as cell cycle and differentiation, transcription, motility, and inflammation [134]. The
clustering of S100A genes within the EDC locus, in addition to evidence supporting their
involvement in epidermal differentiation [135], suggests a biologically-plausible role in
the pathogenesis of skin-related diseases. For instance, elevated serum levels of S100A8
and S100A9 proteins have been shown to be related to abnormal differentiation of
keratinocytes in skin of psoriasis patients [136].
The current state of knowledge suggests that increased methylation of gene
promoters is associated with reduced genes expression; whereas, decreased methylation
is associated with increased gene expression; however, emerging evidence suggest that
such a regulatory role highly depends on the context in which methylation occurs in the
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genome and is not limited to methylation of promoter regions [137, 138]. In this study we
observed that among female participants with eczema as compared to those without
eczema, DNA methylation of cg12048339 (TSS1500 of S100A11 gene) was reduced, on
average, by 1% to 2% across the three study samples. In contrast, DNA methylation of
cg10959711 (TSS1500 of S100A6 gene) among males with eczema as compared to
eczema-free participants was increased, on average, by 1% to 3% across the study
cohorts. Such results suggest that altered methylation of CpG sites within the EDC locus
could serve as markers of eczema in a sex-specific manner.
Existing evidence support the regulatory role of DNA methylation on the activity
of S100A genes [139]. Although we observed associations between DNA methylation in
two CpG sites with eczema, results of this preliminary report should be interpreted with
caution. First, DNA methylation, in this report, was not measured in the respective tissue
of the disease (i.e., skin); therefore, the extent to which DNA methylation measured in
peripheral blood (or cord blood) relate to other tissues and whether can be used as a
biomarker for phenotype variation is unclear and an area of current scientific dispute
[137, 140]. Second, the discrepancy, apart from the two identified CpG sites, in the
results across the three study samples could be due to (i) the differential phenotype
expression over age and/or (ii) the dynamic nature of DNA methylation that changes with
respect to age and environmental exposures. For instance, previously we observed a sexreversal in the prevalence of eczema during adolescence period with more girls
developing eczema and more boys outgrowing their eczema [25], such a sex-switchover
in the risk could be mediated by changes in DNA methylation.
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There is no doubt that this study can only serve as a starting point for future
studies due to the limited sample sizes of the studied cohorts. The discovery cohorts is the
largest sample (n = 367) that we studied and from which we obtained the initial
significant findings. Replications cohorts I and II were smaller in size (n = 146 and n =
94, respectively) and failed to replicate, in terms of statistical significance, results of the
discovery cohort. The sex-specific analyses were based on even smaller groups. This
said, we acknowledge the fact that two out of five CpG sites were in agreement in regard
to their effect sizes across the three study cohorts. Moreover, the observed modest effect
sizes are not unusual, apart from cancer studies, for studies investigating complex
diseases. For example, a 2.07% difference in DNA methylation of the ORMDL3 gene
when comparing asthmatic (87.90%) to non-asthmatic (85.83%) children has been
reported [141]. Currently, there is no consensus as to whether modest changes in DNA
methylation are as important or less important when compared to larger changes in regard
to the development of complex diseases. To this end, previously we demonstrated that an
interaction between genetic variants in the FLG gene with adjacent DNA methylation
predisposed to greater risk of eczema [80]. These results indicated that the association
between FLG loss-of-function variants and eczema is modulated by DNA methylation.
Therefore, simultaneously considering the DNA methylation of the EDC locus and the
underlying genetic variants might provide further insights into the genetics/epigenetics of
eczema than when considering each factor separately. Taken together, future studies
should incorporate DNA methylation, genetic predisposition, gene expression, and
proteins levels to provide a better assessment of the risk.
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In conclusion, this exploratory study demonstrated that DNA methylation of the
EDC genomic region could be an important factor in the development of eczema and
might as well explain some of the observed genome-wide linkage and association signals
relating the EDC locus with eczema. Interestingly, we observed gender-specific
associations between DNA methylation of CpG sites and eczema, which further support
the fact that eczema development is different across the two sexes. Future studies
confirming these preliminary observations are needed and should obtain DNA
methylation profiles from the disease-tissue to increase reliability and relevant of any
findings.
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IOW birth cohort:
n = 1,456

Discovery cohort (F1):
367 participants (245 girls and 122
boys), aged 18 years, had DNA
methylation measurements
New females (n = 9) and
males (n = 40) participants

Females: n = 37
Males: n = 5
Replication cohort I (F2 parents):
146 parents (93 women and 53 men)
had DNA methylation measurements
- Pregnant women had their DNA
methylation measured during early (n
= 66) or late (n = 27) pregnancy
Replication cohort II (F2 Offspring):
94 newborns (43 girls and 51 boys)
had their DNA methylation measured
in cord blood

Figure 5.1. Flow diagram of the different analyzed study samples.
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Females: n = 47
Males: n = 8

Table 5.1. Prevalence of eczema in the different study samples stratified by sex
p-value*

Total

Females

Males

12.6
(46/366)
1

15.2
(37/244)
1

7.4
(9/122)
0

0.034

15.6
(22/141)
5

21.1
(19/90)
3

5.9
(3/51)
2

0.017

21.1
(8/38)
13

0.354

Discovery cohort (F1)
Eczema at age 18 years, % (n/total)
Missing, n
Replication cohort I (F2 parents)
Eczema, % (n/total)
Missing, n
Replication cohort II (F2 offspring)
16.7
11.8
(12/72)
(4/34)
Missing, n
22
9
*
P-value comparing proportions of females to males.
Eczema at age 1 year, % (n/total)
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Table 5.2. Association of CpG sites in the EDC genomic region with eczema status: results of the discovery cohort
Average methylation
(5th – 95th percentile)

Both sexes
CpG ID
cg10959711
cg13493250
cg03969260
cg12048339
cg01910639

Gene
S100A6
LCE1F
SPRR2G
S100A11
S100A6

85

Female participants
cg10959711
S100A6
cg13493250
LCE1F
cg03969260 SPRR2G
cg12048339 S100A11
cg01910639
S100A6

Placement
TSS1500
TSS1500
3ʹ UTR
TSS1500
Body

Average methylation
(5th – 95th percentile)
0.11 (0.07 – 0.16)
0.38 (0.29 – 0.49)
0.93 (0.90 – 0.95)
0.67 (0.62 – 0.72)
0.73 (0.63 – 0.81)

Yes eczema
0.12 (0.09 – 0.19)
0.41 (0.31 – 0.52)
0.94 (0.92 – 0.95)
0.65 (0.61 – 0.69)
0.75 (0.67 – 0.83)

No eczema
0.10 (0.07 – 0.16)
0.38 (0.29 – 0.48)
0.93 (0.91 – 0.94)
0.67 (0.62 – 0.72)
0.72 (0.62 – 0.80)

Effect size
(SE)*
0.02 (0.004)
0.03 (0.010)
0.01 (0.002)
-0.02 (0.005)
0.03 (0.009)

Raw
p-value
0.00023
0.00052
0.00065
0.00118
0.00139

TSS1500
TSS1500
3ʹ UTR
TSS1500
Body

0.11 (0.06 – 0.18)
0.38 (0.29 – 0.50)
0.93 (0.91 – 0.95)
0.67 (0.62 – 0.72)
0.74 (0.62 – 0.82)

0.12 (0.09 – 0.22)
0.40 (0.31 – 0.52)
0.93 (0.92 – 0.95)
0.65 (0.60 – 0.70)
0.75 (0.66 – 0.83)

0.10 (0.06 – 0.17)
0.36 (0.29 – 0.48)
0.92 (0.91 – 0.95)
0.67 (0.62 – 0.72)
0.73 (0.61 – 0.72)

0.02 (0.006)
0.04 (0.011)
0.01 (0.002)
-0.02 (0.005)
0.03 (0.012)

0.0016
0.0012
0.0018
0.0002
0.0066

FDR adj.
p-value
0.055
0.055
0.055
0.071
0.071

Male participants
cg10959711
S100A6
TSS1500
0.10 (0.08 – 0.13)
0.11 (0.09 – 0.16)
0.10 (0.08 – 0.13)
0.01 (0.005)
0.0251
cg13493250
LCE1F
TSS1500
0.39 (0.29 – 0.48)
0.42 (0.28 – 0.49)
0.39 (0.29 – 0.48)
0.03 (0.021)
0.1959
cg03969260 SPRR2G
3ʹ UTR
0.93 (0.91 – 0.94)
0.92 (0.90 – 0.94)
0.93 (0.91 – 0.94)
-0.01 (0.003)
0.9959
cg12048339 S100A11
TSS1500
0.66 (0.62 – 0.71)
0.67 (0.64 – 0.69)
0.66 (0.61 – 0.71)
0.01 (0.011)
0.8144
cg01910639
S100A6
Body
0.71 (0.65 – 0.75)
0.73 (0.67 – 0.76)
0.71 (0.64 – 0.75)
0.02 (0.012)
0.2849
SE: Standard error; FDR: False discovery rate; Ajd.: adjusted
*
Effect size is calculated as average methylation difference between eczema-affected and eczema-free participants using linear regression models. Effect sizes of
the ‘both sexes’ models were adjusted for sex and cell-type composition.

Table 5.3. Association of CpG sites in the EDC genomic region with eczema status: results of the replication cohort I
Average methylation
(5th – 95th percentile)

Both sexes
CpG ID
cg10959711
cg13493250
cg03969260
cg12048339
cg01910639

Gene
S100A6
LCE1F
SPRR2G
S100A11
S100A6

86

Female participants
cg10959711
S100A6
cg13493250
LCE1F
cg03969260 SPRR2G
cg12048339 S100A11
cg01910639
S100A6

Placement
TSS1500
TSS1500
3ʹ UTR
TSS1500
Body

Average methylation
(5th – 95th percentile)
0.09 (0.08 – 0.11)
0.39 (0.29 – 0.51)
0.93 (0.91 – 0.95)
0.67 (0.62 – 0.71)
0.70 (0.63 – 0.74)

Yes eczema
0.10 (0.08 – 0.11)
0.38 (0.29 -0.51)
0.92 (0.90 – 0.95)
0.65 (0.61 – 0.70)
0.69 (0.64 – 0.73)

No eczema
0.09 (0.08 – 0.11)
0.39 (0.31 – 0.51)
0.93 (0.91 – 0.95)
0.67 (0.62 – 0.71)
0.70 (0.63 – 0.74)

Effect size
(SE)*
0.01 (0.003)
-0.01 (0.015)
-0.01 (0.003)
-0.02 (0.007)
-0.01 (0.008)

Raw
p-value
0.8798
0.6788
0.2889
0.2862
0.5078

TSS1500
TSS1500
3ʹ UTR
TSS1500
Body

0.10 (0.08 – 0.11)
0.39 (0.29 – 0.50)
0.93 (0.91 – 0.95)
0.67 (0.61 – 0.70)
0.70 (0.65 – 0.74)

0.10 (0.08 – 0.11)
0.37 (0.24 – 0.53)
0.92 (0.90 – 0.95)
0.65 (0.61 – 0.70)
0.69 (0.60 – 0.73)

0.09 (0.08 – 0.11)
0.38 (0.29 – 0.50)
0.93 (0.91 – 0.95)
0.67 (0.62 – 0.70)
0.70 (0.66 – 0.75)

0.01 (0.005)
-0.01 (0.017)
-0.01 (0.004)
-0.02 (0.007)
-0.01 (0.008)

0.7550
0.4420
0.2898
0.1428
0.3577

Male participants
cg10959711
S100A6
TSS1500
0.09 (0.08 – 0.11)
0.10 (0.09 – 0.11)
0.09 (0.08 – 0.11)
0.01 (0.006)
0.7200
cg13493250
LCE1F
TSS1500
0.39 (0.31 – 0.51)
0.40 (0.39 – 0.51)
0.39 (0.31 – 0.51)
0.01 (0.037)
0.4226
cg03969260 SPRR2G
3ʹ UTR
0.93 (0.91 – 0.94)
0.92 (0.91 – 0.93)
0.93 (0.91 – 0.94)
-0.01 (0.006)
0.9147
cg12048339 S100A11
TSS1500
0.67 (0.62 – 0.72)
0.68 (0.64 – 0.71)
0.67 (0.63 – 0.72)
0.01 (0.019)
0.6263
cg01910639
S100A6
Body
0.68 (0.62 – 0.73)
0.66 (0.65 – 0.72)
0.68 (0.62 – 0.73)
-0.02 (0.023)
0.8495
SE: Standard error; FDR: False discovery rate; Ajd.: adjusted
*
Effect size is calculated as average methylation difference between eczema-affected and eczema-free participants using linear regression models. Effect sizes of
the ‘both sexes’ models were adjusted for sex and cell-type composition.

Table 5.4. Association of CpG sites in the EDC genomic region with eczema status: results of the replication cohort II
Average methylation
(5th – 95th percentile)

Both sexes
CpG ID
cg10959711
cg13493250
cg03969260
cg12048339
cg01910639

Gene
S100A6
LCE1F
SPRR2G
S100A11
S100A6

87

Female participants
cg10959711
S100A6
cg13493250
LCE1F
cg03969260 SPRR2G
cg12048339 S100A11
cg01910639
S100A6

Placement
TSS1500
TSS1500
3ʹ UTR
TSS1500
Body

Average methylation
(5th – 95th percentile)
0.19 (0.12 – 0.26)
0.38 (0.29 – 0.46)
0.92 (0.90 – 0.94)
0.68 (0.63 – 0.73)
0.85 (0.75 – 0.89)

Yes eczema
0.20 (0.09 – 0.33)
0.36 (0.25 – 0.45)
0.91 (0.90 – 0.95)
0.68 (0.63 – 0.73)
0.82 (0.53 – 0.90)

No eczema
0.19 (0.14 – 0.26)
0.38 (0.31 – 0.46)
0.92 (0.89 – 0.94)
0.69 (0.64 – 0.73)
0.84 (0.77 – 0.89)

Effect size
(SE)*
0.01 (0.013)
-0.02 (0.015)
-0.01 (0.004)
-0.01 (0.009)
-0.02 (0.017)

Raw
p-value
0.8056
0.1453
0.9833
0.3941
0.6029

TSS1500
TSS1500
3ʹ UTR
TSS1500
Body

0.19 (0.15 – 0.23)
0.36 (0.27 – 0.45)
0.92 (0.89 – 0.94)
0.68 (0.64 – 0.72)
0.85 (0.77 – 0.89)

0.17 (0.08 – 0.21)
0.32 (0.25 – 0.44)
0.91 (0.90 – 0.92)
0.67 (0.66 – 0.70)
0.83 (0.53 – 0.90)

0.19 (0.15 – 0.23)
0.36 (0.28 – 0.43)
0.92 (0.89 – 0.94)
0.68 (0.64 – 0.72)
0.85 (0.80 – 0.89)

-0.02 (0.015)
-0.04 (0.026)
- 0.01 (0.007)
-0.01 (0.014)
-0.02 (0.033)

0.1489
0.1439
0.3015
0.7898
0.5716

Male participants
cg10959711
S100A6
TSS1500
0.20 (0.11 – 0.28)
0.24 (0.18 – 0.33)
0.21 (0.11 – 0.28)
0.03 (0.018)
0.1938
cg13493250
LCE1F
TSS1500
0.39 (0.32 – 0.46)
0.39 (0.31 – 0.45)
0.40 (0.32 – 0.48)
-0.01 (0.017)
0.5823
cg03969260 SPRR2G
3ʹ UTR
0.92 (0.90 – 0.94)
0.92 (0.90 – 0.95)
0.91 (0.90 – 0.93)
0.01 (0.006)
0.5499
cg12048339 S100A11
TSS1500
0.69 (0.63 – 0.74)
0.68 (0.63 – 0.73)
0.70 (0.63 – 0.74)
-0.02 (0.013)
0.4397
cg01910639
S100A6
Body
0.85 (0.75 – 0.89)
0.86 (0.82 – 0.88)
0.84 (0.73 – 0.89)
0.02 (0.016)
0.3421
SE: Standard error; FDR: False discovery rate; Ajd.: adjusted
*
Effect size is calculated as average methylation difference between eczema-affected and eczema-free participants using linear regression models. Effect sizes of
the ‘both sexes’ models were adjusted for sex and cell-type composition.

CHAPTER 6
DISCUSSION
6.1 SECTION STRUCTURE
In this section I will tie together the major findings of this dissertation and their
relevant interpretation. In general, results of chapters 3 and 4 will by synthesized together
as they were (i) based on the same study sample and (ii) investigated the role of FLG
variants and allergic sensitization on the development of single (chapter 3) and multiple
(chapter 4) allergic diseases. In contrast, results of chapter 5 will be discussed separately
since it was based on three semi-independent study samples and investigated the potential
role of DNA methylation of the EDC genomic locus on the development of eczema.

6.2 OVERVIEW OF FINDINGS
The first two research-related chapters (i.e., chapters 3 and 4) of this dissertation
aimed at elucidating the role of FLG variants and allergic sensitization on the
development of allergic diseases. Chapter 3 focused on the possible effect modification
by allergic sensitization and/or eczema on the association between “FLG variants and
asthma” and “FLG variants and rhinitis”. I demonstrated that both allergic sensitization
and eczema status are possible effect modifiers of the association between FLG variants
and asthma. In contrast, neither eczema nor allergic sensitization modified the association
of FLG variants with rhinitis in a statistically significant manner. In chapter 4, I showed
that the coexistence of eczema, asthma, and rhinitis is prevalent and allergic sensitization
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and FLG variants jointly predisposed to increased risk of allergic comorbidities. On the
other hand, chapter 5 investigated the role of DNA methylation across the EDC genomic
region on the risk of eczema. Results of this exploratory study demonstrated possible
gender-specific associations between DNA methylation of CpG sites and eczema in the
discovery study sample; however, the results, across the three semi-independent study
samples, did not identify consistent pattern of associations between DNA methylation of
CpG sites in EDC locus with eczema

6.3 FLG VARIANTS AND ALLERGIC SENSITIZATION IN RELATION TO ALLERGIC DISEASES
Studies investigating the natural history (long-term prognosis) of allergic diseases
have improved our understanding of the biological mechanisms that underlie the clinical
manifestation of these complex disorders. For instance, in previous reports we have
demonstrated that a sex-switchover in the prevalence of eczema [25], asthma [37], and
rhinitis [33] occurs around puberty, with more adolescent girls being affect. Etiologic
investigations have indicated the importance of environmental, immunologic, and genetic
factors in the pathogenesis of allergic diseases [23, 26, 110, 142-144]. Moreover, close
and complex inter-relatedness between the manifestations of eczema, asthma, and rhinitis
have been demonstrated [45, 48, 103]; however, common mechanisms and pathways
underlying their development is an area of ongoing scientific research. The ‘allergic
march’ concept suggests that allergic disorders develop in a sequential pattern, starting
with eczema in early infancy and later in childhood developing asthma and rhinitis [41,
106]. However, supporting replicable evidence and consensus is far from complete [108,
145, 146]. An opposing concept is the “coexistence” of allergic morbidities [42, 45, 109,
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115]. Therefore, identifying common risk factors that predispose to the development of
single and/or multiple allergic diseases is of importance and will further elucidate the
etiology of such complex diseases.
Allergic sensitization (deviated immune responses) has been widely associated
with different allergic diseases [48, 49, 96]. Similarly, FLG variants (representing
defective epidermal barrier) have recently emerged as strong independent risk factors for
eczema [59]. Furthermore, FLG variants increase the risk of asthma and rhinitis only in
the presence of coexisting eczema [59, 60]. Apart from eczema, it has been suggested
that FLG variants predispose to allergic disorders of the airways by facilitating the
penetration of allergens through the defective epidermal barrier, which in turn might lead
to local and systematic inflammation at distant organs (e.g., lung and nasal tissues) [56,
147]. In this dissertation I have focused on FLG variants and allergic sensitization as they
have been considered as common risk factors that predispose and link the manifestation
of eczema, asthma, and rhinitis [49, 60, 79]. That said, our current state of knowledge
lacks clear understanding on their single and joint role in the development of single
(chapter 3) and multiple (chapter 4) allergic diseases. Utilizing the prospective nature of
the Isle of Wight birth cohort study, I tested if FLG variants interact with allergic
sensitization and/or eczema on the risk of later asthma and rhinitis. Specifically, I
investigated as to whether interplay between “FLG variants and allergic sensitization”
and/or “FLG variants and eczema” predisposed to the development of subsequent asthma
and rhinitis. Next, I tested whether FLG variants and allergic sensitization jointly
predisposed to the coexistence of eczema, asthma, and rhinitis.
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6.3.1 SINGLE ALLERGIC DISEASES
Thus far, FLG variants are the strongest and most replicated genetic risk factors
for eczema development [59, 66]. In a previous report, we have corroborated the reported
association between FLG variants and eczema and further demonstrated that allergic
sensitization is an important effect modifier of this association [79]. We showed that FLG
variants increased the risk of eczema only in the presence of allergic sensitization and the
combined effect of both risk factors was associated with elevated risk of eczema (RR =
2.92, 95% CI: 1.47–5.77) that was above and beyond their individual effects [79]. In this
dissertation, I sought to explore the possibility that allergic sensitization could also
modify the reported associations of FLG variants with asthma and rhinitis.
Prior studies have shown that FLG variants are associated with asthma only in the
presence of coexisting eczema [59, 66]. However, this possible effect modification by
eczema was not consistently demonstrated for the association between FLG variants and
rhinitis [65, 66]. To this end, I have tested the hypothesis that allergic sensitization, rather
than eczema status, modifies the association of FLG variants with asthma and rhinitis. I
have tested my hypothesis under two models: (i) concurrent effect models in which both
the exposure and the outcome coexisted at the same time and (ii) delayed effect models in
which I used the preceding cumulative allergic sensitization status (or eczema status), i.e.
all SPTs results (or eczema status) from assessments that are prior to the outcome
assessment, when testing the interaction between FLG variants and allergic sensitization
(or eczema) on the risk of subsequent asthma/rhinitis.
In stratified analyses (concurrent model), both eczema and allergic sensitization
status modulated the association between FLG variants and asthma. Statistical
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interactions on multiplicative scale were tested to determine whether the observed
heterogonous effects were statistically significantly different. A statistically significant
interaction was found only between FLG variants and allergic sensitization on the risk of
asthma. In delayed effect models, which take the time order of risk factors and disease
occurrences into account, I have tested the interaction of ‘FLG variants with preceding
allergic sensitization’ and ‘FLG variants with preceding eczema’ on the risk of
subsequent asthma. Results of delayed effect models showed that FLG variants in
interaction with preceding allergic sensitization and preceding eczema increased the risk
of subsequent asthma. Hence, indicating that both allergic sensitization and eczema might
act as effect modifiers for the association between FLG variants and asthma.
In regard to rhinitis, results of stratified analyses (concurrent model) demonstrated
that eczema status did not modify the association between FLG variants and rhinitis;
however, this association was modified when stratifying by allergic sensitization status.
But, there was no evidence for an interactive effect (statistical interaction) neither
between FLG variants and eczema nor between FLG variants and allergic sensitization on
the risk for rhinitis. Similarly, results of delayed effect models showed that neither
preceding eczema nor preceding allergic sensitization interacted with FLG variants on the
risk of subsequent rhinitis.
These findings indicate that FLG variants may need eczema and/or allergic
sensitization to execute their adverse effects on asthma. The finding of an interaction
between FLG variants and allergic sensitization in this study improves our understanding
of the possible link between genetics of the epidermal barrier (i.e., FLG variants) and a
respiratory disorder (i.e., asthma). Such an observation further supports the hypothesis
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that cutaneous sensitization priming, partially facilitated by FLG variants, could lead to
local and systematic inflammation at distant organs (e.g., lung) [56, 98]. Our results of an
interactive effect between FLG variants and allergic sensitization on the risk of asthma
and the lack of such interaction on the risk of rhinitis suggest that the pathway through
which FLG variants predispose to asthma and rhinitis may be different. For instance, the
expression of filaggrin protein was not detected in the human bronchial epithelium;
however, it has been shown that filaggrin is expressed in the nasal vestibule [64, 94].
That said, the extent to which filaggrin expression in the nasal vestibular lining influence
the development of rhinitis is yet to be investigated by future studies.
In summary, the first part of this dissertation has demonstrated that (i) FLG
variants are associated with single allergic diseases such as asthma and rhinitis and (ii)
allergic sensitization and eczema status act as possible effect modifiers of the association
between FLG variants and asthma. The combined effects of ‘preceding allergic
sensitization and FLG variants’ and ‘preceding eczema and FLG variants’ increased the
risk of subsequent asthma by 4.93-fold and 3.33-fold, respectively, during the study
period (i.e., the first 18 years of life). In contrast, the association between FLG variants
and rhinitis was not modulated by either allergic sensitization or eczema status. Taken
together, our results demonstrated differential etiological pathways underlying the
development of asthma and rhinitis and future studies corroborating our observations are
needed.
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6.3.2 MULTIPLE ALLERGIC DISEASES
After exploring the role of allergic sensitization and FLG variants on the
development of single allergic diseases, I investigated their single and joint contribution
towards the development of allergic comorbidities (i.e., coexistence of eczema, asthma,
and rhinitis). First, I constructed eight non-overlapping combinations of the three allergic
disorders (Table 2.1), which were used in subsequent analyses for this part of the
dissertation.
Although previous studies have demonstrated the importance of allergic
sensitization and FLG variants on the development of single allergic diseases [49, 60,
96], no prior study have investigated the joint role of both risk factors on the development
of allergic comorbidities. In this dissertation, I have demonstrated that the coexistence of
“eczema, asthma, and rhinitis” affect around 2% of the study population. Both risk
factors, when tested separately, were associated with single and multiple allergic
diseases. However, FLG variants, when adjusting for the effect of allergic sensitization,
did not show any association with allergic disorders. Remarkably, interactions between
the two risk factors were associated with substantial combined effects on the risk of
allergic comorbidities. For instance, a 23-fold increased risk for having “eczema, asthma,
and rhinitis” was associated with the presence of both FLG variants and allergic
sensitization. Moreover, we estimated that approximately 21% to 49% of allergic
comorbidities in the population may be attributed to the presence of both FLG variants
and allergic sensitization.
In summary, results of this part of the dissertation suggests that comorbidities of
eczema, asthma, and rhinitis are prevalent and both allergic sensitization and FLG
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variants are common risk factors that predispose to the comorbidity of allergic disorders.
The combination of both risk factors was associated with elevated risk of coexisting
allergic manifestations. Although in the previous section of this dissertation I showed that
FLG variants and allergic sensitization predispose to single allergic diseases, in this
section I further demonstrated the importance of their joint role on the co-manifestation
of allergic diseases. Therefore, simultaneously considering the contribution of genetic
predisposition toward a defective skin barrier (i.e., FLG variants) and the propensity for
immune dysregulation (i.e., allergic sensitization) provided new and improved insights
into the pathogenesis of allergic disorders.

6.3.3 STRENGTHS AND LIMITATIONS
The first two research-related chapters (i.e., chapters 3 and 4) in this dissertation
were based on information collected in the Isle of Wight birth cohort study. Major
strengths of our prospective study, covering the first 18 years of life, are the repeated
phenotyping, objective assessments of allergic sensitization status, and the low loss to
follow-up (ranged from 5% to 17%). Moreover, the majority (80%) of the study
participants were genotyped for FLG variants common among populations of European
ancestry. We showed, previously, that the genotyped study participants did not differ
from the total cohort with regard to multiple characteristics [79]. Hence, there is no
indication of selection bias that could pose a threat to the validity of our study.
Misclassification of eczema cases is minimal since a high proportion of subjects showed
typical manifestation of eczema in the usual locations (antecubital or popliteal fossae,
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ankles, face or neck for 97% at 1 year, 91% at 2 years, 75% at 4 years, 86% at 10 years
and 76% at 18 years) [25].
Potential limitations are the definition of asthma and rhinitis symptoms in early
life. Our asthma conclusion at ages 10 and 18 years followed the ISAAC criteria [4],
which was at that time not available for assessments at age 1, 2, and 4 years. Although
slightly different methods were used to define asthma, in a previous report we have
shown that the minor change in asthma definition over time did not influence the validity
of our asthma classification (i.e, no noticeable change in asthma prevalence up to 10
years of age) [37]. In addition, since it is difficult to differentiate between infectious and
other forms of rhinitis in infancy, the elevated prevalence at 1-or-2 years might have been
influenced by misclassifying ‘viral induced infectious rhinitis’ [33]. However, by
applying repeated measurements analysis based solely on assessments later in childhood
and adolescence (4, 10, and 18 years), we believe that the influence of the possible
misclassification of rhinitis at 1-or-2 years on the overall results of the study is minimal,
since similar results were obtained. Moreover, since SPTs at age 1-or-2 years were
performed on symptomatic children, we speculate that selection bias leading to
underestimated RRs might have been induced. Although proportions of SPT positivity at
ages 1-or-2 years (20.6%) and 4 years (19.6%; SPT performed irrespective of symptoms)
were similar, RRs associating allergic sensitization at age 1-or-2 years with outcomes
(i.e., eczema, asthma, and rhinitis) at the same age tended to be smaller than RRs relating
allergic sensitization at age 4 years with outcomes at the same age, since also the
reference group had some symptoms. Hence, the estimated RRs at age 1-or-2 might be
underestimated; however, the extent of the possible selection bias is minimal since our
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results did not noticeably change when we excluded the 1-or-2 years follow-up data from
the analyses. Such observations further demonstrate the robustness of the GEE method in
providing population averaged estimates (RRs) while accounting for the within-subject
correlations of repeated measurements.

6.4 DNA METHYLATION OF THE EDC AND ECZEMA RISK
The third research-related chapter (i.e., chapter 5) of this dissertation focused on
the role of DNA methylation across the EDC genomic region in relation to eczema status.
In this explorative study, I have screened for associations between DNA methylation of
256 CpG sites across the EDC locus with eczema status at age 18 years (discovery
cohort), and subsequently replicated the significant findings in two semi-independent
cohorts. Results of this analysis showed that DNA methylation of two CpG sites
(cg10959711 and cg12048339) demonstrated similar effect sizes across the three study
samples. Noticeably, DNA methylation of CpG site cg12048339 was associated with
eczema specifically among female participants of all study cohorts; whereas, DNA
methylation of cg10959711 associated with eczema among male participants in all study
samples. Such results might point towards sex-specific associations between DNA
methylation across the EDC locus and eczema.
Both of the identified sex-specific CpG sites are located within genes that belong
to the S100A gene-family cluster on the EDC locus. The cg12048339 is located within
the promoter region of S100A6 gene, specifically 1500 base-pairs upstream of
transcription start site (TSS1500). Similarly, the cg10959711 is located within the
TSS1500 genomic region of S100A11 gene. The S100A genes, overall, share similar gene
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structure by containing two introns and three exons (exon-2 and exon-3 are translated)
and encode proteins that, in general, contain two calcium-binding EF-hand motifs [134,
135]. The S100A proteins are involved in various biological functions and processes,
such as cell cycle and differentiation, transcription, motility, and inflammation [134]. The
clustering of S100A genes within the EDC locus, in addition to evidence supporting their
involvement in epidermal differentiation [135], suggests a biologically-plausible role in
the pathogenesis of skin-related diseases. In this study we observed that among female
participants with eczema as compared to those without eczema, DNA methylation of
cg12048339 (TSS1500 of S100A11 gene) was reduced, on average, by 1% to 2% across
the three study samples. In contrast, DNA methylation of cg10959711 (TSS1500 of
S100A6 gene) among males with eczema as compared to eczema-free participants was
increased, on average, by 1% to 3% across the study cohorts. Such results suggest that
altered methylation of CpG sites within the EDC locus could serve as markers of eczema
in a sex-specific manner.

6.4.1 STRENGTHS AND LIMITATIONS
There is no doubt that this study can only serve as a starting point for future
studies due to the limited sample sizes of the studied cohorts. The discovery cohorts is the
largest sample (n = 367) that we studied and from which we obtained the initial
significant findings. Replications cohorts I and II were smaller in size (n = 146 and n =
94, respectively) and failed to replicate, in terms of statistical significance, results of the
discovery cohort. The sex-specific analyses were based on even smaller groups.
Moreover, DNA methylation, in this report, was not measured in the respective tissue of
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the disease (i.e., skin); therefore, the extent to which DNA methylation measured in
peripheral blood (or cord blood) relate to other tissues and whether can be used as a
biomarker for phenotype variation is unclear and an area of current scientific dispute
[137, 140]. The discrepancy, apart from the two identified CpG sites, in the results across
the three study samples could be due to (i) the differential phenotype expression over age
and/or (ii) the dynamic nature of DNA methylation that changes with respect to age and
environmental exposures. For instance, previously we observed a sex-reversal in the
prevalence of eczema during adolescence period with more girls developing eczema and
more boys outgrowing their eczema [25], such a sex-switchover in the risk could be
mediated by changes in DNA methylation.

6.5 CONCLUSION
In this dissertation I have investigated the role of FLG variants (representing an
impaired epidermal barrier) and allergic sensitizations (representing deviated immune
responses) on the development of single and multiple allergic diseases. Results of this
dissertation clearly demonstrated that FLG variants and allergic sensitization are common
factors that predispose and link the manifestation of different allergic diseases (i.e.,
eczema, asthma, and rhinitis). First, I have shown that allergic sensitization and eczema
modulated the association between FLG variants and asthma, but not rhinitis. Hence,
implying that the mechanisms and pathways through which FLG variants predispose to
increased risk of asthma and rhinitis may be different. Second, a coexistence of allergic
disorders was demonstrated to be frequent; and allergic sensitization and FLG variants
jointly increased risk of allergic comorbidities. The coexistence of allergic diseases may
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represent more severe and complex clinical phenotypes that require more and longer
medical care. The interactive effect and the elevated proportion of allergic comorbidities
associated with allergic sensitization and FLG variants emphasize their joint importance
in the pathogenesis of allergic disorders. Third, DNA methylation across the EDC
genomic region might influence the risk of eczema in a sex-specific manner.
In summary, this dissertation provided insights on (i) the joint role of FLG
variants and allergic sensitization on the development of single and multiple allergic
diseases and (ii) the role of DNA methylation of the EDC locus on the development of
eczema. Therefore, results of this dissertation helped improve our ability to better identify
and stratify those who share similar risk characteristics, which may also enhance clinical
management and the development of efficient intervention and prevention strategies.
Future studies corroborating our findings of the joint role of FLG variants and allergic
sensitization on the development of single and multiple allergic diseases are needed.
Moreover, future studies confirming our preliminary observations of sex-specific
associations between DNA methylation and eczema are needed and should obtain DNA
methylation profiles from the disease-tissue (i.e., skin) to increase reliability and enhance
relevance of any findings.

100

REFERENCES
1.

Pawankar R, Canonica GW, Holgate ST, Lockey RF. Allergic diseases and
asthma: a major global health concern. Curr Opin Allergy Clin Immunol 2012;
12:39-41.

2.

Suh DC, Sung J, Gause D et al. Economic burden of atopic manifestations in
patients with atopic dermatitis--analysis of administrative claims. J Manag Care
Pharm 2007; 13:778-89.

3.

Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in
preschool children? Br J Dermatol 2001; 144:514-22.

4.

Asher MI, Keil U, Anderson HR et al. International Study of Asthma and
Allergies in Childhood (ISAAC): rationale and methods. Eur Respir J 1995;
8:483-91.

5.

Asher MI, Montefort S, Bjorksten B et al. Worldwide time trends in the
prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in
childhood: ISAAC Phases One and Three repeat multicountry cross-sectional
surveys. Lancet 2006; 368:733-43.

6.

Worldwide variations in the prevalence of asthma symptoms: the International
Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 1998;
12:315-35.

7.

Williams H, Robertson C, Stewart A et al. Worldwide variations in the prevalence
of symptoms of atopic eczema in the International Study of Asthma and Allergies
in Childhood. J Allergy Clin Immunol 1999; 103:125-38.

8.

Worldwide variation in prevalence of symptoms of asthma, allergic
rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of
Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998;
351:1225-32.

9.

Pearce N, Ait-Khaled N, Beasley R et al. Worldwide trends in the prevalence of
asthma symptoms: phase III of the International Study of Asthma and Allergies in
Childhood (ISAAC). Thorax 2007; 62:758-66.

10.

Asher MI. Recent perspectives on global epidemiology of asthma in childhood.
Allergol Immunopathol (Madr) 2010; 38:83-7.

101

11.

Flohr C. Recent perspectives on the global epidemiology of childhood eczema.
Allergol Immunopathol (Madr) 2011; 39:174-82.

12.

Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on
Asthma (ARIA) 2008 update (in collaboration with the World Health
Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 Suppl 86:8-160.

13.

Deckers IA, McLean S, Linssen S et al. Investigating international time trends in
the incidence and prevalence of atopic eczema 1990-2010: a systematic review of
epidemiological studies. PLoS One 2012; 7:e39803.

14.

Odhiambo JA, Williams HC, Clayton TO et al. Global variations in prevalence of
eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol
2009; 124:1251-8 e23.

15.

Anderson HR, Ruggles R, Strachan DP et al. Trends in prevalence of symptoms
of asthma, hay fever, and eczema in 12-14 year olds in the British Isles, 19952002: questionnaire survey. BMJ 2004; 328:1052-3.

16.

Lai CK, Beasley R, Crane J et al. Global variation in the prevalence and severity
of asthma symptoms: phase three of the International Study of Asthma and
Allergies in Childhood (ISAAC). Thorax 2009; 64:476-83.

17.

Ait-Khaled N, Pearce N, Anderson HR et al. Global map of the prevalence of
symptoms of rhinoconjunctivitis in children: The International Study of Asthma
and Allergies in Childhood (ISAAC) Phase Three. Allergy 2009; 64:123-48.

18.

Kauffmann F, Demenais F. Gene-environment interactions in asthma and allergic
diseases: challenges and perspectives. J Allergy Clin Immunol 2012; 130:1229-40;
quiz 41-2.

19.

Bieber T. Atopic dermatitis. N Engl J Med 2008; 358:1483-94.

20.

Sohn A, Frankel A, Patel RV, Goldenberg G. Eczema. Mt Sinai J Med 2011;
78:730-9.

21.

Sabin BR, Peters N, Peters AT. Chapter 20: Atopic dermatitis. Allergy Asthma
Proc 2012; 33 Suppl 1:S67-9.

22.

Bieber T. Atopic dermatitis. Ann Dermatol 2010; 22:125-37.

23.

Biagini Myers JM, Khurana Hershey GK. Eczema in early life: genetics, the skin
barrier, and lessons learned from birth cohort studies. J Pediatr 2010; 157:704-14.

24.

Chen W, Mempel M, Schober W, Behrendt H, Ring J. Gender difference, sex
hormones, and immediate type hypersensitivity reactions. Allergy 2008; 63:141827.

102

25.

Ziyab AH, Raza A, Karmaus W et al. Trends in eczema in the first 18 years of
life: results from the Isle of Wight 1989 birth cohort study. Clin Exp Allergy
2010; 40:1776-84.

26.

Subbarao P, Mandhane PJ, Sears MR. Asthma: epidemiology, etiology and risk
factors. CMAJ 2009; 181:E181-90.

27.

Herzog R, Cunningham-Rundles S. Pediatric asthma: natural history, assessment,
and treatment. Mt Sinai J Med 2011; 78:645-60.

28.

Variations in the prevalence of respiratory symptoms, self-reported asthma
attacks, and use of asthma medication in the European Community Respiratory
Health Survey (ECRHS). Eur Respir J 1996; 9:687-95.

29.

Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma P. The
global burden of asthma: executive summary of the GINA Dissemination
Committee report. Allergy 2004; 59:469-78.

30.

Koterba AP, Saltoun CA. Chapter 9: Asthma classification. Allergy Asthma Proc
2012; 33 Suppl 1:S28-31.

31.

Spycher BD, Silverman M, Kuehni CE. Phenotypes of childhood asthma: are they
real? Clin Exp Allergy 2010; 40:1130-41.

32.

Mucci T, Govindaraj S, Tversky J. Allergic rhinitis. Mt Sinai J Med 2011;
78:634-44.

33.

Kurukulaaratchy RJ, Karmaus W, Raza A et al. The influence of gender and
atopy on the natural history of rhinitis in the first 18 years of life. Clin Exp
Allergy 2011; 41:851-9.

34.

Kurukulaaratchy RJ, Karmaus W, Arshad SH. Sex and atopy influences on the
natural history of rhinitis. Curr Opin Allergy Clin Immunol 2012; 12:7-12.

35.

Postma DS. Gender differences in asthma development and progression. Gend
Med 2007; 4 Suppl B:S133-46.

36.

Vink NM, Postma DS, Schouten JP, Rosmalen JG, Boezen HM. Gender
differences in asthma development and remission during transition through
puberty: the TRacking Adolescents' Individual Lives Survey (TRAILS) study. J
Allergy Clin Immunol 2010; 126:498-504 e1-6.

37.

Soto-Ramirez N, Ziyab AH, Karmaus W et al. Epidemiologic methods of
assessing asthma and wheezing episodes in longitudinal studies: measures of
change and stability. J Epidemiol 2013; 23:399-410.

38.

Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for
asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000; 106:S201-5.

103

39.

Bugiani M, Carosso A, Migliore E et al. Allergic rhinitis and asthma comorbidity
in a survey of young adults in Italy. Allergy 2005; 60:165-70.

40.

Demoly P, Bousquet J. The relation between asthma and allergic rhinitis. Lancet
2006; 368:711-3.

41.

Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy
Asthma Immunol 2010; 105:99-106; quiz 07-9, 17.

42.

Sun HL, Yeh CJ, Ku MS, Lue KH. Coexistence of allergic diseases: patterns and
frequencies. Allergy Asthma Proc 2012; 33:e1-4.

43.

Ober C, Yao TC. The genetics of asthma and allergic disease: a 21st century
perspective. Immunol Rev 2011; 242:10-30.

44.

Yuksel H, Dinc G, Sakar A et al. Prevalence and comorbidity of allergic eczema,
rhinitis, and asthma in a city in western Turkey. J Investig Allergol Clin Immunol
2008; 18:31-5.

45.

Illi S, von Mutius E, Lau S et al. The natural course of atopic dermatitis from
birth to age 7 years and the association with asthma. J Allergy Clin Immunol
2004; 113:925-31.

46.

Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier
and immune dysregulation. Immunol Rev 2011; 242:233-46.

47.

Torres-Borrego J, Molina-Teran AB, Montes-Mendoza C. Prevalence and
associated factors of allergic rhinitis and atopic dermatitis in children. Allergol
Immunopathol (Madr) 2008; 36:90-100.

48.

Tan RA, Corren J. The relationship of rhinitis and asthma, sinusitis, food allergy,
and eczema. Immunol Allergy Clin North Am 2011; 31:481-91.

49.

Arshad SH, Tariq SM, Matthews S, Hakim E. Sensitization to common allergens
and its association with allergic disorders at age 4 years: a whole population birth
cohort study. Pediatrics 2001; 108:E33.

50.

Johansson SG, Lundahl J. Asthma, atopy, and IgE: what is the link? Curr Allergy
Asthma Rep 2001; 1:89-90.

51.

Weidinger S, Baurecht H, Naumann A, Novak N. Genome-wide association
studies on IgE regulation: are genetics of IgE also genetics of atopic disease?
Curr Opin Allergy Clin Immunol 2010; 10:408-17.

52.

Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol 2008;
8:205-17.

104

53.

Palmer CN, Irvine AD, Terron-Kwiatkowski A et al. Common loss-of-function
variants of the epidermal barrier protein filaggrin are a major predisposing factor
for atopic dermatitis. Nat Genet 2006; 38:441-6.

54.

Kubo A, Nagao K, Amagai M. Epidermal barrier dysfunction and cutaneous
sensitization in atopic diseases. J Clin Invest 2012; 122:440-7.

55.

Cork MJ, Danby SG, Vasilopoulos Y et al. Epidermal barrier dysfunction in
atopic dermatitis. J Invest Dermatol 2009; 129:1892-908.

56.

O'Regan GM, Irvine AD. The role of filaggrin in the atopic diathesis. Clin Exp
Allergy 2010; 40:965-72.

57.

Akiyama M. FLG mutations in ichthyosis vulgaris and atopic eczema: spectrum
of mutations and population genetics. Br J Dermatol 2010; 162:472-7.

58.

Baurecht H, Irvine AD, Novak N et al. Toward a major risk factor for atopic
eczema: meta-analysis of filaggrin polymorphism data. J Allergy Clin Immunol
2007; 120:1406-12.

59.

Rodriguez E, Baurecht H, Herberich E et al. Meta-analysis of filaggrin
polymorphisms in eczema and asthma: robust risk factors in atopic disease. J
Allergy Clin Immunol 2009; 123:1361-70 e7.

60.

Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and
allergic diseases. N Engl J Med 2011; 365:1315-27.

61.

O'Regan GM, Sandilands A, McLean WH, Irvine AD. Filaggrin in atopic
dermatitis. J Allergy Clin Immunol 2008; 122:689-93.

62.

Henderson J, Northstone K, Lee SP et al. The burden of disease associated with
filaggrin mutations: a population-based, longitudinal birth cohort study. J Allergy
Clin Immunol 2008; 121:872-7 e9.

63.

Marenholz I, Nickel R, Ruschendorf F et al. Filaggrin loss-of-function mutations
predispose to phenotypes involved in the atopic march. J Allergy Clin Immunol
2006; 118:866-71.

64.

Weidinger S, O'Sullivan M, Illig T et al. Filaggrin mutations, atopic eczema, hay
fever, and asthma in children. J Allergy Clin Immunol 2008; 121:1203-09 e1.

65.

Schuttelaar ML, Kerkhof M, Jonkman MF et al. Filaggrin mutations in the onset
of eczema, sensitization, asthma, hay fever and the interaction with cat exposure.
Allergy 2009; 64:1758-65.

66.

van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing
allergic sensitisation and allergic disorders: systematic review and meta-analysis.
BMJ 2009; 339:b2433.

105

67.

Bussmann C, Weidinger S, Novak N. Genetics of atopic dermatitis. J Dtsch
Dermatol Ges 2011; 9:670-6.

68.

Brown SJ, McLean WH. Eczema genetics: current state of knowledge and future
goals. J Invest Dermatol 2009; 129:543-52.

69.

Bataille V, Lens M, Spector TD. The use of the twin model to investigate the
genetics and epigenetics of skin diseases with genomic, transcriptomic and
methylation data. J Eur Acad Dermatol Venereol 2012; 26:1067-73.

70.

van Vliet J, Oates NA, Whitelaw E. Epigenetic mechanisms in the context of
complex diseases. Cell Mol Life Sci 2007; 64:1531-8.

71.

Talens RP, Boomsma DI, Tobi EW et al. Variation, patterns, and temporal
stability of DNA methylation: considerations for epigenetic epidemiology.
FASEB J 2010; 24:3135-44.

72.

Heijmans BT, Mill J. Commentary: The seven plagues of epigenetic
epidemiology. Int J Epidemiol 2012; 41:74-8.

73.

Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell 2007;
128:669-81.

74.

Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A. Genes encoding
structural proteins of epidermal cornification and S100 calcium-binding proteins
form a gene complex ("epidermal differentiation complex") on human
chromosome 1q21. J Invest Dermatol 1996; 106:989-92.

75.

Segre JA. Epidermal differentiation complex yields a secret: mutations in the
cornification protein filaggrin underlie ichthyosis vulgaris. J Invest Dermatol
2006; 126:1202-4.

76.

Henry J, Toulza E, Hsu CY et al. Update on the epidermal differentiation
complex. Front Biosci (Landmark Ed) 2012; 17:1517-32.

77.

Wolf R, Wolf D. Abnormal epidermal barrier in the pathogenesis of atopic
dermatitis. Clin Dermatol 2012; 30:329-34.

78.

Proksch E, Folster-Holst R, Brautigam M et al. Role of the epidermal barrier in
atopic dermatitis. J Dtsch Dermatol Ges 2009; 7:899-910.

79.

Ziyab AH, Karmaus W, Yousefi M et al. Interplay of filaggrin loss-of-function
variants, allergic sensitization, and eczema in a longitudinal study covering
infancy to 18 years of age. PLoS One 2012; 7:e32721.

80.

Ziyab AH, Karmaus W, Holloway JW et al. DNA methylation of the filaggrin
gene adds to the risk of eczema associated with loss-of-function variants. J Eur
Acad Dermatol Venereol 2013; 27:e420-3.

106

81.

Kypriotou M, Huber M, Hohl D. The human epidermal differentiation complex:
cornified envelope precursors, S100 proteins and the 'fused genes' family. Exp
Dermatol 2012; 21:643-9.

82.

Hoffjan S, Stemmler S. On the role of the epidermal differentiation complex in
ichthyosis vulgaris, atopic dermatitis and psoriasis. Br J Dermatol 2007; 157:4419.

83.

Arshad SH, Karmaus W, Kurukulaaratchy R et al. Polymorphisms in the
interleukin 13 and GATA binding protein 3 genes and the development of eczema
during childhood. Br J Dermatol 2008; 158:1315-22.

84.

Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm
Venereol Suppl (Stockh) 1980; 92:44-47.

85.

Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting
DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.

86.

Bibikova M, Barnes B, Tsan C et al. High density DNA methylation array with
single CpG site resolution. Genomics 2011; 98:288-95.

87.

Kuan PF, Wang S, Zhou X, Chu H. A statistical framework for Illumina DNA
methylation arrays. Bioinformatics 2010; 26:2849-55.

88.

Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous
outcomes. Biometrics 1986; 42:121-30.

89.

Steenland K, Armstrong B. An overview of methods for calculating the burden of
disease due to specific risk factors. Epidemiology 2006; 17:512-9.

90.

Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable
fractions. Am J Public Health 1998; 88:15-9.

91.

Du P, Zhang X, Huang CC et al. Comparison of Beta-value and M-value methods
for quantifying methylation levels by microarray analysis. BMC Bioinformatics
2010; 11:587.

92.

Bock C. Analysing and interpreting DNA methylation data. Nat Rev Genet 2012;
13:705-19.

93.

Brown SJ, McLean WH. One remarkable molecule: filaggrin. J Invest Dermatol
2012; 132:751-62.

94.

De Benedetto A, Qualia CM, Baroody FM, Beck LA. Filaggrin expression in oral,
nasal, and esophageal mucosa. J Invest Dermatol 2008; 128:1594-7.

95.

Ying S, Meng Q, Corrigan CJ, Lee TH. Lack of filaggrin expression in the human
bronchial mucosa. J Allergy Clin Immunol 2006; 118:1386-8.

107

96.

Busse WW. The role of allergy in disease. Immunol Rev 2011; 242:5-9.

97.

Marenholz I, Kerscher T, Bauerfeind A et al. An interaction between filaggrin
mutations and early food sensitization improves the prediction of childhood
asthma. J Allergy Clin Immunol 2009; 123:911-6.

98.

Heimall J, Spergel JM. Filaggrin mutations and atopy: consequences for future
therapeutics. Expert Rev Clin Immunol 2012; 8:189-97.

99.

Poninska J, Samolinski B, Tomaszewska A et al. Filaggrin gene defects are
independent risk factors for atopic asthma in a Polish population: a study in
ECAP cohort. PLoS One 2011; 6:e16933.

100.

Li M, Chen X, Chen R, Bao Y, Yao Z. Filaggrin gene mutations are associated
with independent atopic asthma in Chinese patients. Allergy 2011; 66:1616-7.

101.

Ekelund E, Lieden A, Link J et al. Loss-of-function variants of the filaggrin gene
are associated with atopic eczema and associated phenotypes in Swedish families.
Acta Derm Venereol 2008; 88:15-9.

102.

Greenland S. Interactions in epidemiology: relevance, identification, and
estimation. Epidemiology 2009; 20:14-7.

103.

Martinez FD, Wright AL, Taussig LM et al. Asthma and wheezing in the first six
years of life. The Group Health Medical Associates. N Engl J Med 1995;
332:133-8.

104.

Reed CE. The natural history of asthma. J Allergy Clin Immunol 2006; 118:543-8;
quiz 49-50.

105.

Williams HC, Strachan DP. The natural history of childhood eczema:
observations from the British 1958 birth cohort study. Br J Dermatol 1998;
139:834-9.

106.

Zheng T, Yu J, Oh MH, Zhu Z. The atopic march: progression from atopic
dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res 2011;
3:67-73.

107.

Barberio G, Pajno GB, Vita D et al. Does a ‘reverse’ atopic march exist? Allergy
2008; 63:1630-32.

108.

Williams H, Flohr C. How epidemiology has challenged 3 prevailing concepts
about atopic dermatitis. J Allergy Clin Immunol 2006; 118:209-13.

109.

Ballardini N, Kull I, Lind T et al. Development and comorbidity of eczema,
asthma and rhinitis to age 12: data from the BAMSE birth cohort. Allergy 2012;
67:537-44.

108

110.

Holloway JW, Yang IA, Holgate ST. Genetics of allergic disease. J Allergy Clin
Immunol 2010; 125:S81-94.

111.

Roberts G, Zhang H, Karmaus W et al. Trends in cutaneous sensitization in the
first 18 years of life: results from the 1989 Isle of Wight birth cohort study. Clin
Exp Allergy 2012; 42:1501-9.

112.

Gutowska-Owsiak D, Ogg GS. Cytokine regulation of the epidermal barrier. Clin
Exp Allergy 2013; 43:586-98.

113.

Wagner B, Li J, Liu H, Guo G. Gene-environment correlation: difficulties and a
natural experiment-based strategy. Am J Public Health 2013; 103 Suppl 1:S16773.

114.

Wang IJ, Lin TJ, Kuo CF et al. Filaggrin polymorphism P478S, IgE level, and
atopic phenotypes. Br J Dermatol 2011; 164:791-6.

115.

Pinart M, Benet M, Annesi-Maesano I et al. Comorbidity of eczema, rhinitis, and
asthma in IgE-sensitised and non-IgE-sensitised children in MeDALL: a
population-based cohort study. Lancet Respir Med 2014; 2:131-40.

116.

van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young
children with atopic eczema: a systematic review. J Allergy Clin Immunol 2007;
120:565-9.

117.

Dharmage SC, Lowe AJ, Matheson MC et al. Atopic dermatitis and the atopic
march revisited. Allergy 2014; 69:17-27.

118.

Almqvist C, Li Q, Britton WJ et al. Early predictors for developing allergic
disease and asthma: examining separate steps in the 'allergic march'. Clin Exp
Allergy 2007; 37:1296-302.

119.

Lowe AJ, Abramson MJ, Hosking CS et al. The temporal sequence of allergic
sensitization and onset of infantile eczema. Clin Exp Allergy 2007; 37:536-42.

120.

Osman M, Tagiyeva N, Wassall HJ et al. Changing trends in sex specific
prevalence rates for childhood asthma, eczema, and hay fever. Pediatr Pulmonol
2007; 42:60-5.

121.

Burr ML, Dunstan FD, Hand S, Ingram JR, Jones KP. The natural history of
eczema from birth to adult life: a cohort study. Br J Dermatol 2013; 168:1339-42.

122.

Esparza-Gordillo J, Weidinger S, Folster-Holst R et al. A common variant on
chromosome 11q13 is associated with atopic dermatitis. Nat Genet 2009; 41:596601.

109

123.

Greisenegger EK, Zimprich F, Zimprich A, Gleiss A, Kopp T. Association of the
chromosome 11q13.5 variant with atopic dermatitis in Austrian patients. Eur J
Dermatol 2013; 23:142-5.

124.

Marenholz I, Rivera VA, Esparza-Gordillo J et al. Association screening in the
Epidermal Differentiation Complex (EDC) identifies an SPRR3 repeat number
variant as a risk factor for eczema. J Invest Dermatol 2011; 131:1644-9.

125.

Stemmler S, Nothnagel M, Parwez Q et al. Variation in genes of the epidermal
differentiation complex in German atopic dermatitis patients. Int J Immunogenet
2009; 36:217-22.

126.

Cookson WO, Ubhi B, Lawrence R et al. Genetic linkage of childhood atopic
dermatitis to psoriasis susceptibility loci. Nat Genet 2001; 27:372-3.

127.

Paternoster L, Zhurov AI, Toma AM et al. Genome-wide association study of
three-dimensional facial morphology identifies a variant in PAX3 associated with
nasion position. Am J Hum Genet 2012; 90:478-85.

128.

Weidinger S, Willis-Owen SA, Kamatani Y et al. A genome-wide association
study of atopic dermatitis identifies loci with overlapping effects on asthma and
psoriasis. Hum Mol Genet 2013; 22:4841-56.

129.

Morar N, Cookson WO, Harper JI, Moffatt MF. Filaggrin mutations in children
with severe atopic dermatitis. J Invest Dermatol 2007; 127:1667-72.

130.

Rozek LS, Dolinoy DC, Sartor MA, Omenn GS. Epigenetics: relevance and
implications for public health. Annu Rev Public Health 2014; 35:105-22.

131.

Soto-Ramirez N, Arshad SH, Holloway JW et al. The interaction of genetic
variants and DNA methylation of the interleukin-4 receptor gene increase the risk
of asthma at age 18 years. Clin Epigenetics 2013; 5:1.

132.

Houseman EA, Accomando WP, Koestler DC et al. DNA methylation arrays as
surrogate measures of cell mixture distribution. BMC Bioinformatics 2012; 13:86.

133.

Koestler DC, Christensen B, Karagas MR et al. Blood-based profiles of DNA
methylation predict the underlying distribution of cell types: a validation analysis.
Epigenetics 2013; 8:816-26.

134.

Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from
evolution to function and pathology (including an update of the nomenclature).
Biochem Biophys Res Commun 2004; 322:1111-22.

135.

Eckert RL, Broome AM, Ruse M et al. S100 proteins in the epidermis. J Invest
Dermatol 2004; 123:23-33.

110

136.

Benoit S, Toksoy A, Ahlmann M et al. Elevated serum levels of calcium-binding
S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of
keratinocytes in psoriasis. Br J Dermatol 2006; 155:62-6.

137.

Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and
beyond. Nat Rev Genet 2012; 13:484-92.

138.

Shenker N, Flanagan JM. Intragenic DNA methylation: implications of this
epigenetic mechanism for cancer research. Br J Cancer 2012; 106:248-53.

139.

Lesniak W. Epigenetic regulation of S100 protein expression. Clin Epigenetics
2011; 2:77-83.

140.

Terry MB, Delgado-Cruzata L, Vin-Raviv N, Wu HC, Santella RM. DNA
methylation in white blood cells: association with risk factors in epidemiologic
studies. Epigenetics 2011; 6:828-37.

141.

Michel S, Busato F, Genuneit J et al. Farm exposure and time trends in early
childhood may influence DNA methylation in genes related to asthma and allergy.
Allergy 2013; 68:355-64.

142.

Flohr C, Mann J. New insights into the epidemiology of childhood atopic
dermatitis. Allergy 2014; 69:3-16.

143.

Brunekreef B, Von Mutius E, Wong GK et al. Early life exposure to farm animals
and symptoms of asthma, rhinoconjunctivitis and eczema: an ISAAC Phase Three
Study. Int J Epidemiol 2012; 41:753-61.

144.

Brunekreef B, Von Mutius E, Wong G et al. Exposure to cats and dogs, and
symptoms of asthma, rhinoconjunctivitis, and eczema. Epidemiology 2012;
23:742-50.

145.

Barberio G, Pajno GB, Vita D et al. Does a 'reverse' atopic march exist? Allergy
2008; 63:1630-2.

146.

Hopper JL, Bui QM, Erbas B et al. Does eczema in infancy cause hay fever,
asthma, or both in childhood? Insights from a novel regression model of sibling
data. J Allergy Clin Immunol 2012; 130:1117-22 e1.

147.

De Benedetto A, Kubo A, Beck LA. Skin barrier disruption: a requirement for
allergen sensitization? J Invest Dermatol 2012; 132:949-63.

111

APPENDIX A – PERMISSION TO REPRINT

JOHN WILEY AND SONS LICENSE
TERMS AND CONDITIONS
Jun 01, 2014

This is a License Agreement between Ali H Ziyab ("You") and John Wiley and Sons ("John Wiley and
Sons") provided by Copyright Clearance Center ("CCC"). The license consists of your order details,
the terms and conditions provided by John Wiley and Sons, and the payment terms and
conditions.

All payments must be made in full to CCC. For payment instructions, please see
information listed at the bottom of this form.
License Number

3400311068211

License date

Jun 01, 2014

Licensed content publisher

John Wiley and Sons

Licensed content publication

Clinical & Experimental Allergy

Licensed content title

Allergic sensitization and filaggrin variants predispose to the
comorbidity of eczema, asthma, and rhinitis: results from the
Isle of Wight birth cohort

Licensed copyright line

This article is protected by copyright. All rights reserved.

Licensed content author

Ali H. Ziyab,Wilfried Karmaus,Hongmei Zhang,John W.
Holloway,Susan E. Steck,Susan Ewart,Syed Hasan Arshad

Licensed content date

Apr 8, 2014

Start page

n/a

End page

n/a

Type of use

Dissertation/Thesis

Requestor type

Author of this Wiley article

Format

Print and electronic

Portion

Full article

Will you be translating?

No

112

Title of your thesis / dissertation

Role of Allergic Sensitization, Filaggrin Variants, and
DNA Methylation on the Risk of Allergic Disorders

Expected completion date

Aug 2014

Expected size (number of pages)

125

Total

0.00 USD

Terms and Conditions

TERMS AND CONDITIONS
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc.
or one of its group companies (each a"Wiley Company") or handled on behalf of a society
with which a Wiley Company has exclusive publishing rights in relation to a particular
work (collectively "WILEY"). By clicking �accept� in connection with completing this
licensing transaction, you agree that the following terms and conditions apply to this
transaction (along with the billing and payment terms and conditions established by the
Copyright Clearance Center Inc., ("CCC's Billing and Payment terms and conditions"), at
the time that you opened your Rightslink account (these are available at any time
at http://myaccount.copyright.com).

Terms and Conditions
•

The materials you have requested permission to reproduce or reuse (the "Wiley
Materials") are protected by copyright.

•

You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-alone
basis), non-transferable, worldwide, limited license to reproduce the Wiley Materials for
the purpose specified in the licensing process. This license is for a one-time use only and
limited to any maximum distribution number specified in the license. The first instance of
republication or reuse granted by this licence must be completed within two years of the
date of the grant of this licence (although copies prepared before the end date may be
distributed thereafter). The Wiley Materials shall not be used in any other manner or for
any other purpose, beyond what is granted in the license. Permission is granted subject to
an appropriate acknowledgement given to the author, title of the material/book/journal
and the publisher. You shall also duplicate the copyright notice that appears in the Wiley
publication in your use of the Wiley Material. Permission is also granted on the
understanding that nowhere in the text is a previously published source acknowledged for
all or part of this Wiley Material. Any third party content is expressly excluded from this
permission.

•

With respect to the Wiley Materials, all rights are reserved. Except as expressly granted by
the terms of the license, no part of the Wiley Materials may be copied, modified, adapted
(except for minor reformatting required by the new Publication), translated, reproduced,
transferred or distributed, in any form or by any means, and no derivative works may be
made based on the Wiley Materials without the prior permission of the respective
copyright owner. You may not alter, remove or suppress in any manner any copyright,

113

trademark or other notices displayed by the Wiley Materials. You may not license, rent,
sell, loan, lease, pledge, offer as security, transfer or assign the Wiley Materials on a standalone basis, or any of the rights granted to you hereunder to any other person.
•

The Wiley Materials and all of the intellectual property rights therein shall at all times
remain the exclusive property of John Wiley & Sons Inc, the Wiley Companies, or their
respective licensors, and your interest therein is only that of having possession of and the
right to reproduce the Wiley Materials pursuant to Section 2 herein during the
continuance of this Agreement. You agree that you own no right, title or interest in or to
the Wiley Materials or any of the intellectual property rights therein. You shall have no
rights hereunder other than the license as provided for above in Section 2. No right,
license or interest to any trademark, trade name, service mark or other branding ("Marks")
of WILEY or its licensors is granted hereunder, and you agree that you shall not assert any
such right, license or interest with respect thereto.

•

NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR REPRESENTATION OF ANY
KIND TO YOU OR ANY THIRD PARTY, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO
THE MATERIALS OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF
MERCHANTABILITY, ACCURACY, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR
PURPOSE, USABILITY, INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED BY YOU

•

WILEY shall have the right to terminate this Agreement immediately upon breach of this
Agreement by you.
You shall indemnify, defend and hold harmless WILEY, its Licensors and their respective
directors, officers, agents and employees, from and against any actual or threatened
claims, demands, causes of action or proceedings arising from any breach of this
Agreement by you.

•

•

IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR ANY OTHER PARTY OR
ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL,
INDIRECT, EXEMPLARY OR PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR
IN CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE
MATERIALS REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH OF
CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT OR OTHERWISE
(INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES,
USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER OR NOT THE
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION
SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED
REMEDY PROVIDED HEREIN.

•

Should any provision of this Agreement be held by a court of competent jurisdiction to be
illegal, invalid, or unenforceable, that provision shall be deemed amended to achieve as
nearly as possible the same economic effect as the original provision, and the legality,
validity and enforceability of the remaining provisions of this Agreement shall not be
affected or impaired thereby.

114

•

The failure of either party to enforce any term or condition of this Agreement shall not
constitute a waiver of either party's right to enforce each and every term and condition of
this Agreement. No breach under this agreement shall be deemed waived or excused by
either party unless such waiver or consent is in writing signed by the party granting such
waiver or consent. The waiver by or consent of a party to a breach of any provision of this
Agreement shall not operate or be construed as a waiver of or consent to any other or
subsequent breach by such other party.

•

This Agreement may not be assigned (including by operation of law or otherwise) by you
without WILEY's prior written consent.

•

Any fee required for this permission shall be non-refundable after thirty (30) days from
receipt by the CCC.

•

These terms and conditions together with CCC�s Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you and
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes all
prior agreements and representations of the parties, oral or written. This Agreement may
not be amended except in writing signed by both parties. This Agreement shall be binding
upon and inure to the benefit of the parties' successors, legal representatives, and
authorized assigns.

•

In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC�s Billing and Payment terms and conditions,
these terms and conditions shall prevail.

•

WILEY expressly reserves all rights not specifically granted in the combination of (i) the
license details provided by you and accepted in the course of this licensing transaction, (ii)
these terms and conditions and (iii) CCC�s Billing and Payment terms and conditions.

•

This Agreement will be void if the Type of Use, Format, Circulation, or Requestor Type was
misrepresented during the licensing process.

•

This Agreement shall be governed by and construed in accordance with the laws of the
State of New York, USA, without regards to such state�s conflict of law rules. Any legal
action, suit or proceeding arising out of or relating to these Terms and Conditions or the
breach thereof shall be instituted in a court of competent jurisdiction in New York County
in the State of New York in the United States of America and each party hereby consents
and submits to the personal jurisdiction of such court, waives any objection to venue in
such court and consents to service of process by registered or certified mail, return receipt
requested, at the last known address of such party.

WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription
journals offering Online Open. Although most of the fully Open Access journals publish
open access articles under the terms of the Creative Commons Attribution (CC BY) License
only, the subscription journals and a few of the Open Access Journals offer a choice of
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Creative Commons Licenses:: Creative Commons Attribution (CC-BY) license Creative
Commons Attribution Non-Commercial (CC-BY-NC) license and Creative Commons
Attribution Non-Commercial-NoDerivs (CC-BY-NC-ND) License. The license type is
clearly identified on the article.
Copyright in any research article in a journal published as Open Access under a Creative
Commons License is retained by the author(s). Authors grant Wiley a license to publish the
article and identify itself as the original publisher. Authors also grant any third party the
right to use the article freely as long as its integrity is maintained and its original authors,
citation details and publisher are identified as follows: [Title of Article/Author/Journal Title
and Volume/Issue. Copyright (c) [year] [copyright owner as specified in the Journal]. Links
to the final article on Wiley�s website are encouraged where applicable.
The Creative Commons Attribution License
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and
transmit an article, adapt the article and make commercial use of the article. The CC-BY
license permits commercial and non-commercial re-use of an open access article, as long as
the author is properly attributed.
The Creative Commons Attribution License does not affect the moral rights of authors,
including without limitation the right not to have their work subjected to derogatory
treatment. It also does not affect any other rights held by authors or third parties in the
article, including without limitation the rights of privacy and publicity. Use of the article
must not assert or imply, whether implicitly or explicitly, any connection with, endorsement
or sponsorship of such use by the author, publisher or any other party associated with the
article.
For any reuse or distribution, users must include the copyright notice and make clear to
others that the article is made available under a Creative Commons Attribution license,
linking to the relevant Creative Commons web page.
To the fullest extent permitted by applicable law, the article is made available as is and
without representation or warranties of any kind whether express, implied, statutory or
otherwise and including, without limitation, warranties of title, merchantability, fitness for a
particular purpose, non-infringement, absence of defects, accuracy, or the presence or
absence of errors.
Creative Commons Attribution Non-Commercial License
The Creative Commons Attribution Non-Commercial (CC-BY-NC) License permits use,
distribution and reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.(see below)
Creative Commons Attribution-Non-Commercial-NoDerivs License
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The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND)
permits use, distribution and reproduction in any medium, provided the original work is
properly cited, is not used for commercial purposes and no modifications or adaptations are
made. (see below)
Use by non-commercial users
For non-commercial and non-promotional purposes, individual users may access,
download, copy, display and redistribute to colleagues Wiley Open Access articles, as well
as adapt, translate, text- and data-mine the content subject to the following conditions:
•

The authors' moral rights are not compromised. These rights include the right of
"paternity" (also known as "attribution" - the right for the author to be identified as such)
and "integrity" (the right for the author not to have the work altered in such a way that the
author's reputation or integrity may be impugned).

•

Where content in the article is identified as belonging to a third party, it is the obligation of
the user to ensure that any reuse complies with the copyright policies of the owner of that
content.

•

If article content is copied, downloaded or otherwise reused for non-commercial research
and education purposes, a link to the appropriate bibliographic citation (authors, journal,
article title, volume, issue, page numbers, DOI and the link to the definitive published
version on Wiley Online Library) should be maintained. Copyright notices and disclaimers
must not be deleted.

•

Any translations, for which a prior translation agreement with Wiley has not been agreed,
must prominently display the statement: "This is an unofficial translation of an article that
appeared in a Wiley publication. The publisher has not endorsed this translation."

Use by commercial "for-profit" organisations
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes
requires further explicit permission from Wiley and will be subject to a fee. Commercial
purposes include:
•

Copying or downloading of articles, or linking to such articles for further redistribution,
sale or licensing;

•

Copying, downloading or posting by a site or service that incorporates advertising with
such content;

•

The inclusion or incorporation of article content in other works or services (other than
normal quotations with an appropriate citation) that is then available for sale or licensing,
for a fee (for example, a compilation produced for marketing purposes, inclusion in a sales
pack)
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•

Use of article content (other than normal quotations with appropriate citation) by forprofit organisations for promotional purposes

•

Linking to article content in e-mails redistributed for promotional, marketing or
educational purposes;

•

Use for the purposes of monetary reward by means of sale, resale, licence, loan, transfer
or other form of commercial exploitation such as marketing products

•

Print reprints of Wiley Open Access articles can be purchased
from:corporatesales@wiley.com

Further details can be found on Wiley Online
Libraryhttp://olabout.wiley.com/WileyCDA/Section/id-410895.html

Other Terms and Conditions:

v1.9
If you would like to pay for this license now, please remit this license along with your
payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be
invoiced within 48 hours of the license date. Payment should be in the form of a check
or money order referencing your account number and this invoice number 501317106.
Once you receive your invoice for this order, you may pay your invoice by credit card.
Please follow instructions provided at that time.
Make Payment To:
Copyright Clearance Center
Dept 001
P.O. Box 843006
Boston, MA 02284-3006
For suggestions or comments regarding this order, contact RightsLink Customer
Support:customercare@copyright.com or +1-877-622-5543 (toll free in the US) or +1978-646-2777.
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable
license for your reference. No payment is required.
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